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CD31 mediates homophilic interactions between leukocytes and macrophages during 
inflammation, apoptotic cells remain attached and are engulfed whereas viable cells 
actively detach.  We hypothesised that differential recruitment of signalling and 
adapter molecules to the cytoplasmic domain were responsible for the disengagement 
of the viable leukocyte from macrophages. Investigation with a static attachment 
assay using THP-1 as a macrophage model showed the ITIM of CD31 on the 
leukocyte was important for viable cell detachment.  Our data also implicated a role 
for the recruitment of SHP-2 which we attempted to knock-down by siRNA 
delivered by lentivirus.   
SHP-2, in addition to its phosphatase activity, also acts as a docking protein.  To 
examine for potential interacting partners we fused the cytoplasmic domain of CD31 
to GST which we used in pulldown assays from lysates of viable and apoptotic 
leukocytes.  We demonstrated that the recruitment of SHP-1 and SHP-2 were 
dependent on an intact ITIM (immunoreceptor tyrosine-based inhibitory motif). 
Interestingly, apoptotic cell lysates promoted dephosphorylation of the in vitro 
phosphorylated GST-CD31, suggesting an increase in phosphatase activity in aged 
neutrophils.  We were unable to demonstrate an interaction between the cytoplasmic 
domain of CD31 with putative binding partners β-catenin, src, RasGAPp120, 
RhoGAPp190, talin or calmodulin.  
A proteomic approach by MALDI-TOF and MS/MS identified Hsp90 as a novel 






3ε bound to phosphorylated CD31, whereas eIF3 specifically bound to an ITIM 
double tyrosine mutant.  The binding of Hsp90 to CD31 was proposed to occur via a 
TPR motif within the cytoplasmic domain of CD31 which comprises a surface fold 
of basic amino acids complexing a highly acidic carboxy tail of Hsp90.  Truncation 
and site directed mutagenesis of the cytoplasmic domain revealed multiple binding 
sites for Hsp90; specifically two regions containing the sequences 
(KAFYLRKAKAK), previously shown to be the calmodulin binding region, and a 
novel area (SNNEKMSDMEANSHY) which has significant homology with other 
TPR-containing proteins.  Systematic mutagenesis of the putative basic charged 
amino acids within the cytoplasmic domain of CD31 which may mediate the 
interaction with Hsp90 also supports the presence of a TPR motif.   
The importance of Hsp90, 14-3-3ε and eIF3 is currently unknown, although it is 
interesting to note that CD31 was recently found within this laboratory to associate 
with the voltage-gated potassium channel HERG which also binds 14-3-3ε and 
Hsp90.  eIF3 is an RNA helicase that may link CD31 and leukocyte motility to 
spreading initiation centres where motility can be viewed as a rapid turnover of focal 
adhesion complexes.  Together, these studies have identified novel binding partners 
of CD31 may form a macromolecular complex to promote CD31-dependent 













1.1 Leukocyte Migration  
Leukocyte migration through the endothelium is an essential process allowing an 
efficient immune response to invasion by micro-organisms.  The route by which 
leukocytes are able to reach the site of infection is controlled by various forms of 
adhesion and chemoattractants.  The leukocyte initially mediates rolling adhesion 
along the endothelium via L-selectin on the leukocyte and E-selectin and P-selectin 
on the endothelial cell.  This initial tethering gives way to firmer integrin-mediated 
adhesion and arrest of the leukocyte which is shear resistant.  Integrins cycle between 
affinity states, leading to the activation of the immunoglobulin superfamily members.  
The leukocyte is then capable of diapedesis through the endothelium to the site of 
chemoattractant 1. 
 
CD31 is intimately involved in the migration of leukocytes through vascular 
endothelium. CD31 has previously been shown to regulate β1 and β2 integrins during 
leukocyte adhesion to the endothelium, where an intact cytoplasmic domain was 
required, and the small GTPase Rap1 became activated 2.  Stromal derived factor-1 
(SDF-1) induced transmigration of CD34+ myeloid progenitor cells through IL-1β 
stimulated bone marrow endothelium was shown to require CD31 and β1 and β2 
integrins, where CD31 may be transmitting signals leading to integrin activation and 







In T cells, CD31 was found to enhance β1 and β2 integrin-mediated adhesion, 
amplifying the adhesion of the T cell to the endothelium 4. CD31 concentrated at the 
junctions of endothelial cells mediates adhesive interactions that activate β2 integrins 
in an adhesion cascade 5. CD31 regulates migration of T cells acting as an adhesion 
amplifier, upregulating β1 integrin adhesion of the T cell to the endothelium.  This 
increases the adhesion of the T cell to a firm adhesion that facilitates transendothelial 
migration 4.  The recruitment of neutrophils to sites of inflammation is also mediated 
by CD31, where it upregulates α6β1 integrin surface expression.  The upregulation 
allows the neutrophils to migrate through the perivascular basement membrane 6.  
Ligation of CD31 on NK cells upregulates β2 integrins during extravasation into 
inflamed tissues 7. 
 
Fab (fragment antigen binding) crosslinking of CD31 on neutrophils and 
macrophages lead to the activation of β2 integrins showing CD31 participates in 
integrin activation in leukocyte migration 8. Intravital microscopy experiments with 
the murine cremaster muscle demonstrated an in vivo role for homophilic CD31 
interactions between leukocytes and endothelium.  IL-1β induced migration of 
neutrophils showed the integrin α6β1 was upregulated on the transmigrated cells, 
which could assist their migration through the basement membrane 6. 
The integrin αvβ3 has previously been shown to be a ligand for CD31 9.  During 
leukocyte migration in a model of transmigration through rat mesenteric venule 
endothelial cells, blocking antibodies against CD31 prevented IL-1β-induced 






blocked transmigration in response to fMLP (formyl-methionyl-leucyl-
phenylalanine), a synthetic peptide that induces integrin activation 10, a CD31-
independent mechanism of migration, showed that although both CD31 and αvβ3 
were involved in leukocyte transmigration, αvβ3 may not be acting as a ligand for 
CD31 in vivo 11.    Eosinophil adhesion to activated endothelium showed CD31 
activated αvβ3 and increased the adhesion of α4β1 to fibronectin.  The increase in 
adhesion was shown to require the heterophilic CD31- αvβ3 interaction to upregulate 
β1 integrin-mediated adhesion 12. 
 
During monocyte migration, CD31 in the endothelial cell was recycled around the 
transmigrating monocyte in subjunctional reticulum, a membrane compartment 
found at the cell border beneath the membrane.  The reticulum is a collection of 
vesicles connected to each other and the membrane, and CD31 cycles along the 
membrane as the monocyte migrates between the endothelial cells 13. 
 
1.2 The Inhibitory Receptors of the Immunoglobulin Superfamily 
The inhibitory receptors of the immunoglobulin superfamily are expressed on a 
variety of haematopoietic cells and serve to negatively regulate activating receptors 
such as the T cell receptor (TCR), and the B cell receptor, (BCR).  TCR and BCR 
both contain an activation motif termed the ITAM (immunoreceptor tyrosine based 
activation motif).  The ITAM corresponds to a particular sequence (YXXL/I [X6-8] 






domain containing proteins such as kinases to bind and transmit signals downstream 
leading to an activation response.  The inhibitory receptors contain an ITIM 
(immunoreceptor tyrosine based inhibitory motif) sequence is ([I/V/L/S]-X-Y-XX-
[L/V]).  Once phosphorylated the ITIM bind SH2 domain containing phosphatases 
SHP-1 and SHP-2, and SHIP, a polyinositol 5′-phosphate phosphatase, these 
phosphatases  signal downstream to inhibit activated signalling  14. 
 
1.2.1 SIRPα 
SIRPα (signal regulatory protein alpha) is an IgSF member, with three extracellular 
Ig-like domains, a single transmembrane spanning region and a cytoplasmic domain.  
The cytoplasmic domain contains four motifs that correspond to an ITIM 
configuration.  SIRPα is expressed on haematopoietic and neuronal cells, and 
becomes phosphorylated on its ITIM after integrin-mediated cell adhesion, leading to 
association with SHP-1 and SHP-2, phosphatases.  In fibroblasts expressing a 
cytoplasmic domain deficient SIRPα, SHP-2 was unable to associate and the cells 
had increased focal adhesions and actin stress fibres.  Rho activity was also impaired, 
leading to defects in polarised migration 15.   
From bone marrow derived macrophages (BMDM), SIRPα was found to associate 
with two other tyrosine phosphorylated proteins, pp55 and pp130.  This association 
was independent of SHP-1 and tyrosine phosphorylation of SIRPα, signifying the 
ability of SIRPα to act as a scaffolding molecule to allow other proteins to bind and 






SIRPα engagement by its ligand CD47 on dendritic cells (DC) regulates their 
function by providing negative signals that result in the suppression of inflammatory 
cytokine release 17.  In human melanoma cells, SIRPα-CD47 interactions prevented 
cell migration by providing negative signals through the dissociation from SHP-2 18.   
 
1.2.2 Killer Immunoglobulin-like Receptors 
The killer immunoglobulin-like receptors (KIR) are inhibitory receptors on the 
surface of natural killer (NK) cells, and inhibit NK activation following ligation by 
MHC I on target cells. Natural killer cells lyse cells that are infected with virus, or 
tumour cells where MHC I is typically downregulated.  The KIR signal through 
ITIM motifs on the cytoplasmic domain, when the receptor binds ligand, the ITIM 
becomes phosphorylated and recruits SHP-1 19.  The ITIM of KIR was shown to be 
essential in mediating the inhibitory signal as mutation of the tyrosines to 
phenylalanine abrogated the inhibitory effect of the receptor 20.  Specifically, the N-
terminal ITIM was shown to be more effective in mediating the inhibitory signal 21.   
SHP-1 binding to the KIR initiates a pathway that inhibits positive signalling through 
MHC I.  Vav1 is a guanidine-nucleotide exchange factor of Rac that binds to the 
KIR/SHP-1 complex and may prevent the cytoskeletal rearrangement necessary for 
activating signalling 22.  SHP-2 is also recruited to the KIR cytoplasmic domain, and 
requires only the N-terminal ITIM, whereas SHP-1 requires both to be present, as 
studies with chimeric KIRs in vivo have shown 23.  SHP-2 recruited to the ITIM 
prevents NK cell cytotoxicity, and mutating the catalytic region of SHP-2 reverses 








1.2.3 FcγRIIb Receptor 
The FcγRIIb receptor on B cells also has an ITIM that inhibits activation via the B 
cell receptor (BCR).  The phosphorylated ITIM binds SHIP (SH-2-containing 
inositol 5-phosphatase), which in turn binds Dok (downstream of tyrosine kinases), 
Dok is capable of binding RasGAP, which is an exchange factor for Ras 25.  This 
leads to the inhibition of calcium signalling in the B cell, and inhibition of its 
activation through coaggregation with the BCR26-28.   
Regulation of mast cell activation through coaggregation of FcγRIIb and FcεRI 
occurs through the phosphorylation of FcγRIIb by Lyn, and subsequent association 
of the inositol phosphatase SHIP.  SHIP dephosphorylates phosphatidylinositol (3, 4, 
5) triphosphate and prevents downstream calcium mobilisation 28. 
FcγRIIb is also present in activated mature T cells.  The receptor serves to regulate T 
cell activation through a similar mechanism to B cells, with tyrosine phosphorylation 
of SHIP upon coaggregation with the TCR (T cell receptor), and inhibition of 
downstream signalling 29.      
 
1.2.4 CD155 
Studies with CD155, a cell adhesion molecule expressed on fibroblasts with a similar 
structure to CD31, have shown it also has an ITIM motif in its cytoplasmic domain; 






adhesion was reduced and cell migration enhanced, and these effects were prevented 
with the transfection of a point mutation of the ITIM 30. 
 
1.3 The CD31 Molecule 
1.3.1 CD31 Expression 
Platelet-cell adhesion molecule-1 (PECAM-1) or CD31 is a 130kDa glycosylated 
protein found on the surface of endothelial cells, platelets, monocytes, neutrophils 
and a unique subset of T cells, with expression on naïve CD4+ cells and memory 
CD8+ cells 4.  The molecule is composed of six immunoglobulin-like extracellular 
domains, a single transmembrane spanning region and a 118 amino acid cytoplasmic 















Figure 1.3:1.  Cell adhesion molecules  SIRPα, KIR, FcγRIIb , CD31 and CD155 
showing the extracellular immunoglobulin-like domains, the transmembrane spanning 



















1.3.2 CD31 Gene Organisation 
The gene for CD31 is organised into sixteen exons, one for each of for the six 
extracellular domains, one for the transmembrane region, and unusually for a cell 
adhesion molecule, the cytoplasmic domain is encoded by seven individual exons.  











Figure 1.3:2.  Exon/intron map of CD31 showing exons 1-6 encoding the extracellular 
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From alternative splicing of the cytoplasmic exons, many variants of CD31 have 
been discovered. A soluble form exists from the alternative splicing and truncation of 
the genome at exon 9.  Other cell adhesion molecules, including ICAM-1 also 
produce a soluble form.  Both cells of the myeloid system and HUVECs have been 
shown to secrete the soluble form of CD31, and this form was also biologically 
active, capable of preventing aggregation of L cells.  Interestingly, two isoforms of 
CD31 were observed in human plasma, a 90kDa and a 120kDa form.  The 90kDa 
form is truncated at the transmembrane region and does not have the cytoplasmic 
domain, whereas the 120kDa form does have the cytoplasmic domain present 32. 
 
In the developing embryo, CD31 isoforms have been detected during different stages 
of development, having functionally distinct features. The isoforms detected were 
(Δ12,15) and (Δ14,15).  Both isoforms were able to form homophilic interactions 
upon transfection into L-cells, but differed in their sensitivity to antibodies against 
CD31.  This suggested that the deletion of parts of the cytoplasmic domain affected 
the ability of CD31 to bind to ligands 33.  Cells switching between isoforms may 
provide a mechanism by which CD31 can modify adhesive contacts.  Δ15 and 
Δ14/Δ15 expression modulates cadherin adhesion 34, and there is differential 
expression of these isoforms from the early stages of endothelial cell migration 35. 
Of interest is the expression of Δ14 isoform, which does not have tyrosine 686, part 
of the ITIM that is required for SHP-2 binding and subsequent signalling.  Switching 






highlights the possibility that CD31 may have different roles in haematopoiesis and 
vasculogenesis during the process of development 36. 
 
1.4 CD31 Knockout Mouse 
CD31 knockout mice (CD31KO) were generated by disruption of exon 6-8, resulting 
in no protein expression on a C57BL/6 background, and have been shown to be 
viable and fertile.  There were no differences observed in platelet, red blood cell or 
leukocyte counts between wild-type and knockout mice.  Although there was no 
defect in the ability of leukocytes to migrate into areas of inflammation, CD31KO 
neutrophils were unable to migrate past the basement membrane.  This defect was 
only observed when the cells were stimulated by IL-1β 37.   
 
1.4.1 CD31 Models of Inflammation 
CD31KO mice generated on a FVB/n background also have no difference in their 
total blood and leukocyte cell counts.  However, their response to inflammation is 
markedly different compared with the original strain of knockout mice.  Upon 
thioglycollate-induced peritonitis, the CD31KO FVB/n mice show reduced numbers 
of neutrophils, monocytes and macrophages, but the C57BL/6 does not.  C57BL/6 
mice have the unique ability to compensate for the lack of CD31, so perhaps further 
studies should be carried out in other strains of mice 38.    Chronic inflammatory lung 
disease leading to fibrosis was observed in CD31KO FVB/n mice, but not in 
CD31KO C57BL/C, also highlighting the effect of background strains in 







Studies with different models of inflammation have elucidated a role for CD31 in 
leukocyte migration. A model of leukocyte transmigration with rat mesenteric 
venules showed treatment of the rat with anti-CD31 antibodies did not prevent IL-
1β-induced transmigration through the junctions, but the leukocytes were prevented 
from migrating through the basement membrane 40.  Studies with the CD31KO 
mouse cremaster model of inflammation have shown CD31 and the integrin α6β1 is 
required for the migration of leukocytes through the perivascular basement 
membrane 6.   
 
Allergic responses involve mast cell degranulation, and existing therapy involves 
anti-inflammatory drugs, an alternative may be to activate molecules involved in the 
negative regulation of the immune response.  Using both CD31KO and wild-type 
mice, it was shown Ig-E mediated anaphylaxis, and mast cell degranulation was 
enhanced in knockout mice.  This suggests that CD31 may serve to dampen an 
allergic immune response by negatively regulating mast cell activation 41. 
 
PVA sponges implanted into wild-type and CD31KO mice showed differences in 
their vascularisation.  In the knockout animals, the amount of angiogenesis was 
reduced compared with wild-type.  This may explain why in the CD31KO mouse, 
there is reduced leukocyte accumulation, as there are fewer vessels responsible for 






B cells deficient in CD31 show hyperproliferation upon IgM stimulation.  However, 
the ability to produce antibody was not affected.  During maturation of the B cell, 
absence of CD31 causes developmental defect in the transition from the immature to 
the mature cell.  CD31 was found to negatively regulate the B cell receptor, and may 
do this by recruitment of signalling molecules to its cytoplasmic domain.  By 
providing negative signals, CD31 may assist in the maintenance of tolerance, as 
CD31KO mice produced anti-dsDNA antibodies 43. 
 
Although the CD31KO mouse is able to form endothelial junctions and adhesions in 
the absence of CD31, the response to LPS-induced endotoxic shock results in much 
reduced survival compared with wild-type.  The CD31KO mice had increased 
vascular permeability, and increased apoptosis of spleen, liver and kidney, with 
elevated levels of inflammatory cytokines.  Also reduced were the STAT3 (signal 
transducers and activators of transcription) levels.  This suggested CD31 acts as a 
scaffold for STAT3 where it can be phosphorylated, and SHP-2 is able to bind and 
have its activity regulated.  CD31 is also reported to bind tyrosine phosphorylated β-
catenin, and is able to facilitate the dephosphorylation of β-catenin by also binding 
SHP-2.  Dephosphorylated β-catenin was then released and was able to associate 
with VE-cadherin, reassembling the junctional adhesion complex and the integrity of 
the endothelium.  In the absence of CD31, the regulation of these signalling 
molecules is impaired, leading to the increased permeability observed.  CD31 is 







Murine experimental autoimmune encephalitis (EAE) is a model of human multiple 
sclerosis that studies demyelinating disease caused by inflammation in the CNS.  
This involves the induction of autoimmune T cells by administration of a myelin 
oligodendrocyte glycoprotein peptide 45, the migration of these cells across the 
blood-brain barrier, and the initiation and maintenance of inflammation in the CNS.  
Using CD31KO mice to stimulate this response, there was an early beginning of 
clinical symptoms, with increased migration of leukocytes across the blood-brain 
barrier, and a reduced ability to restore the endothelium.  This increased permeability 
could explain the earlier onset of symptoms, and show CD31 to be essential for 
maintaining blood-brain barrier reliability 46. 
 
A murine collagen-induced arthritis model highlighted the role of CD31 in 
negatively regulating immune responses to inflammation.  Type-II collagen (CII) 
was administered, stimulating production of CII specific T cells, and antibody 
production by B cells.  The second stage was where the T cells migrated to the joints 
and caused and maintained inflammation.  CD31KO mice develop arthritis more 
quickly, with increased activation of T cells, and early production of anti-CII 
antibodies, there was also an increased number of infiltrating lymphocytes.  In this 
model, CD31 was not required for leukocyte migration, but for the negative 
regulation of the immune response 47.  Studies on inflammation in the lung revealed 
CD31 dependent and independent responses.  The CD31 responses were due to a 
defect in macrophage activation, with reduced  Fcγ-mediated phagocytosis and 






1.5 CD31 Ligand 
CD31 on endothelial cells localises to cell-cell junctions of confluent monolayers 49, 
where CD31 interacts with itself in homophilic binding to another CD31 molecule on 
the surface of the endothelial cell, this interaction is mediated by the first two 
immunoglobulin-like domains 50.   
Other ligands for CD31 include CD38, a 45kDa glycoprotein expressed on 
endothelial cells and leukocytes with multiple functions including ADP-ribosyl 
cyclase activity, activating NK, B and T cells and as a selectin, mediating leukocyte 
tethering to endothelial cells. Inhibition of CD38-mediated adhesion by monoclonal 
antibody immunoprecipitation and reactivity with CD31-transfected cells suggested 
CD31 is capable of heterophilic interactions 51. 
The integrin avβ3 is expressed on B, T, NK and mast cells amongst other cells types, 
and is comprised of two chains, alpha and beta.  Integrins serve to mediate adhesive 
interactions during cell adhesion and migration, and avβ3 has been shown to act as a 
heterophilic ligand for CD31 during leukocyte adhesion to the endothelium in vitro 
52.  Using CD31 recombinant proteins and the leukemic pro-monocyte cell line 
U937, the cells bound CD31 mostly in a heterotypic manner, with the binding site for 
avβ3 in domain 1 9.  In T cells a 120kDa ligand  for CD31 was discovered which 
when bound to CD31 decreased T cell activation after T cell receptor-ligand 
interactions 53. 
 






Src family kinases have been implicated in phosphorylating the cytoplasmic domain 
of CD31.  Co-precipitation studies showed CD31 is phosphorylated by c-src, 
particularly on Y663 and Y686, this association is mediated by the SH2 domains of 
c-src 54.   As inhibitors of src family kinases did not block the phosphorylation of 
CD31 in stimulated endothelial cells, other kinases may be involved in this particular 
signalling pathway.  Fer is a ubiquitously expressed tyrosine kinase which 
phosphorylates p120-catenin and β-catenin in the adherens junction of endothelial 
cells.  CD31 present at these junctions are tyrosine phosphorylated by Fer, which 
localises to microtubules in migrating cells 55. Studies with murine CD31 showed 
that CD31 is phosphorylated by src and csk kinases, and only on tyrosine 686, there 
was no phosphorylation of tyrosine 663.  csk substrates are usually the C-terminal 
tyrosine residue of src kinases 56. 
 
Tyrosine phosphorylation of the cytoplasmic domain of CD31 allows the SH-2 
domain containing phosphatases SHP-1 and SHP-2 to bind via its SH-2 domains, at 
tyrosine residues Y663 and Y686, part of the ITIM motif  57.  In T cells, CD31 
becomes tyrosine phosphorylated after cross-linking to the T cell receptor or to itself, 
and recruits SHP-2.  This prevented intracellular calcium release and activation of 
the cell 58. 
 
1.5.2 Role of the ITIM of CD31  
The role of the ITIM of CD31 in cell migration has been controversial.  Transfecting 






CD31 demonstrated the ITIM of CD31 was required for the cells to migrate.  The 
study postulated that tyrosine phosphorylation of CD31 acted to negatively regulate 
migration and required the recruitment of SHP-2 to these tyrosines to remove the 
inhibition 59.  Another study exploring the role of the ITIM in endothelial cell 
migration showed that transfection with Y686F CD31, cells had increased migration, 
which implied the ITIM acted as a brake to regulate migration.  During endothelial 
cell migration, homophilic interactions between CD31 are lost, with a subsequent 
loss of tyrosine phosphorylation, and no recruitment of SHP-2 60.  A study by the 
same group measuring wound healing migration with transfected REN cells showed 
there was no difference in migration with cells transfected with either Y663F/Y686F 
or wild-type CD31; but that transfection of these constructs was enough to restore the 
migration defect when compared with knock-out cells.  The defect in knock-out cell 
migration was attributed to an imbalance of Rac and Rho, with less RhoGTP present 
in knock-out cells 61. 
 
1.6 CD31-Mediated Signalling 
CD31 has no intrinsic enzymatic activity and must associate with other proteins via 
its cytoplasmic domain to participate in intracellular signalling. The protein tyrosine 
phosphatases SHP-1 57 and SHP-2 62 have been shown to bind CD31.  A study with a 
mesothelioma cell line expressing a Y663F/Y686F mutant CD31, which could not 
bind SHP-2 showed impaired migration when compared with cells expressing wild-
type CD31.  SHP-1 has been shown to require the ITIM of CD31 intact to bind, 







Tyrosine phosphorylated β-catenin has been shown to bind endothelial cell CD31 64, 
and is thought to sequester β-catenin away from cadherins in the cell junction, 
allowing SHP-2 to bind and dephosphorylate β-catenin, which then dissociates from 
CD31 and can return to the adherens junction, thus leading to the loosening of the 
cell-cell contacts to facilitate migration 65. γ-catenin is a molecule that participates in 
adherens junctions, and binds to CD31 cytoplasmic domain in EOMA cells. The 
association is regulated by PKC, where an increase of PKC serine/threonine 
phosphorylation decreased the amount of γ-catenin binding.  The association is much 
lower than that observed for β-catenin 66. 
 
The inositol phosphatase SHIP has been shown to bind to the cytoplasmic domain of 
CD31 in chicken DT40 B cells independently of tyrosine phosphorylation, and 
regulate the activation of the B cell receptor through a different pathway from the 
recruitment of SHP-1 and SHP-2 62.   A GST fusion protein of the cytoplasmic 
domain also found SHIP capable of binding to CD31, however, this study showed 
that tyrosine 686 was required for binding 63.  Therefore, there is some controversy 
over the residues of CD31 required to recruit SHIP.  SHIP has been shown to bind to 
the ITIM, and another downstream tyrosine residue of the FcγRIIb receptor on B 
cells and negatively regulate B cell activation.  SHIP can also function as a docking 
protein by recruiting RasGAP, which converts the active GTP-bound form of Ras to 
the inactive GDP-bound form 67.   CD31 could conceivably be participating in this 







Signal transducer and activation of transcription 5 (STAT 5) has been shown to bind 
to the cytoplasmic domain of CD31 in vivo during murine development, and require 
tyrosine 701 68.  STAT5 participates in receptor activated JAK (Janus kinase) 
signalling, and becomes phosphorylated where it translocates to the nucleus and 
binds to STAT5 recognition sequences and regulates transcription.  STAT5 
activation is regulated by SOCS (suppressors of cytokines signalling), and SHP-1 
and SHP-2 phosphatases 69.  CD31 may be capable of influencing intracellular 
signalling through this pathway. 
 
The SH2 domain containing signalling protein Grb2 has recently been shown to 
associate with crosslinked tyrosine phosphorylated CD31 on bEND cells (murine 
brain endothelial cells).  Grb2, along with CrkI and Shc are then thought to activate 
the MAPK (mitogen activation protein kinase) and ERK (extracellular related 
kinase) pathway.  This leads to the activation of the small GTPase Ras, which could 
impact upon cell migration 70. 
 
Gab1 (Grb-associated binder 1) bound to tyrosine phosphorylated CD31 on 
mechanically stressed endothelial cells.  Gab1 has plecstrin homology domains, an 
SH3 domain and a BTAM (biphosphotyrosyl activation motif) that recruits SHP-2 71.  







The SH2 domain of Phospholipase C-γ (PLC-γ) has also been shown to bind to the 
cytoplasmic domain of CD31 in a study using BIAcore analysis.  PLC-γ bound 
preferentially to tyrosine 663 63, and the SH3 domain of PLC-γ has more recently 
been shown to act as a guanidine exchange factor for the GTPase PIKE 
(phosphatidylinositol-3’ kinase [PI3K] enhancer).  PIKE stimulates nuclear PI3K 
activity 73.  PI3K has also been shown to bind to the cytoplasmic domain of CD31.  
Ligation of CD31 on human neutrophils induced PI3K association and upregulation 
of β1 integrins 74. 
 
Talin is a 270kDa protein composed of a globular head, and rod domain.  The head 
domain contains a FERM (4.1-ezrin, radexin, moesin) motif.   Talin binds to β-
integrin cytoplasmic domains 75 and links integrins and the extracellular matrix  76 or 
the adhesive contacts between cells 77.  CD31 has also been shown to activate β1 
integrins, and may be associating with talin for this integrin activation (Dr David 
Critchley, Leicester University, UK, personal communication). 
When integrins are activated, src family kinases and FAK (focal adhesion kinase) 
and phosphatases become switched on, allowing rapid phosphorylation and 
dephosphorylation of proteins involved in focal adhesions 78. Talin is in a folded 
conformation when inactive, and binding sites for integrin cytoplasmic domains are 
exposed 79 following activation by cleavage by calpain 80 or upon binding of the 
phosphoinositide PI4,5P2  
In a study where talin was knocked out in ES cells, the cells were unable to spread on 






In C. elegans, talin was found to co-localise in focal-adhesion structures in a 
complex with integrins, vinculin and actin 81.  Using RNAi to knock down talin in C. 
elegans, there were defects in migration in gonadal tissues, and uncoordination and 
paralysis, showing the essential role that talin plays in coordinating cell migration 82. 
The known and postulated binding partners of CD31 are summarised (Table 1.6:1), 
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Src  BAECS 
Talin NIH3T3 







1.7 CD31 and Apoptosis 
CD31 expressed on viable human neutrophils when ligated homophilically with 
CD31 upon macrophages promoted leukocyte detachment.  The detachment signal 
led to the movement of the neutrophil away from the macrophage, whereas CD31 
engagement on apoptotic leukocytes allowed firm tethering and subsequent 
engulfment of the apoptotic cell.  Dissection of the signalling pathway showed SHP-
1 did not associate with CD31, and SHP-2 was cleaved by caspases in apoptotic cells  
84.  Apoptotic B cell lines have also been shown to interact with CD31 on 
macrophages, when CD31 was blocked with antibodies, phagocytosis of apoptotic 
cells was reduced.  70% of the apoptotic population expressed CD31, which 
suggested CD31 was upregulated on dying cells to afford clearance 85. 
Neutrophils express CD47, the ligand for the immunoglobulin superfamily member 
SIRPα.  This interaction in viable neutrophils was reported to lead to ‘don’t eat me’ 
signals, when this interaction was blocked by Fab fragments, the cells were engulfed.  
CD47 was found to be distributed away from the cellular uptake receptors 
calreticulin and PS 86. 
 
1.7.1 CD31 and Cell Survival 
Transmigrated CD14+/CD34+/CD31 expressing mononuclear cells were protected 
from apoptosis by CD31 engagement on endothelial cells during transmigration.  
CD31 was found to deliver anti-apoptotic signals to the transmigrated cells.  The 
signals were in the form of CD31 inducing PI3K activation of Akt, which lead to 






cell undergoing apoptosis 87.  CD31 requires its cytoplasmic domain intact, and 
prevents the release of cytochrome C, caspase activation and nuclear condensation 
which is indicative of Bax-induced apoptosis, thus protecting leukocytes from 
programmed cell death88.  Monocytes protected endothelial cells from apoptosis by 
engaging CD31 on the surface of the cell.  When CD31 interactions were blocked by 
a monoclonal antibody, the protective effect was lost 89.   
Endothelial cell serum-starvation and subsequent apoptosis was found to be inhibited 
by CD31 homophillic engagement, and may require intracellular signalling 
molecules associated with the cytoplasmic domain of CD31 90.  Sphingosine kinase 
(SK) has been shown to signal through CD31 to prevent endothelial cell apoptosis, 
by activating PI3K/Akt pathway 91. 
 
During apoptosis of endothelial cells, CD31 was cleaved into a soluble 100kDa 
fragment composed of the extracellular domain which was shed into the culture 
medium; and a 28kDa truncated form comprising of a small extracellular region, the 
transmembrane section and the cytoplasmic domain.  The truncated form was shown 
to differentially recruit β-catenin, γ-catenin and SHP-2 when compared with full-
length CD31.  Expression of the truncated form only within SW480 cells 
demonstrated a decrease in viable cell number and an increase in apoptosis.  The 
increase in apoptosis correlated with the activation of p38/JNK.  The truncated form 
of CD31 may be taking on a conformation similar to that of the phosphorylated form, 






neutrophils, CD31 was found to be slightly downregulated 93, which may provide 
evidence in haemopoetic cells that cleavage of CD31 occurs. 
 
1.8 SHP-1 and SHP-2 Knock-Out Mouse 
The moth-eaten mouse is deficient in the protein tyrosine phosphatase SHP-1.  The 
phenotype exists as the moth-eaten (me/me), and moth-eaten viable (mev/mev).  
me/me mice have no SHP-1 protein and live for about three weeks, during which 
they develop severe autoimmunity, characterised by reduced proliferation of B, T 
and NK cells, and hyperglobulinemia autoantibody expression, inflammatory lesions 
and pneumonitis.  The mev/mev mouse lives for about nine weeks, and exhibits a 
more chronic immunological phenotype.  mev/mev mice have a catalytically inactive 
SHP-1 and develop an overgrowth of macrophages in the skin and lungs, which 
causes fatal pneumonitis 94. 
Studies with the mev/mev mouse showed SHP-1 was required for the detachment of 
macrophages from αmβ2 integrin, and the detachment required membrane-associated 
PI3K regulation by SHP-1.  The phenotype of the mev/mev mouse may be due to 
failure of macrophages to de-adhere normally in the tissues 95.  A study with mev/mev 
B cells transduced with hen-egg lysozyme (HEL) showed an increase in calcium 
release in response to HEL binding and a reduced threshold for elimination which 
implicates SHP-1 in negative regulation of B cell development 96.   
SHP-2 knockout mice were shown to be embryonic lethal with major developmental 






erythroid cells were found in SHP-2 KO embryos 97.  Specifically, SHP-2 was found 
to be required for lymphopoiesis, where chimeric ES cells (of SHP-2 and Rag-2 
which are unable to rearrange V, D and J chains and thus any lymphopoiesis must 
have been from the SHP-2 cells) were unable to produce functional T or B cells 98.   
A targeted deletion of exon 3, which resulted in a disruption of the N-terminal of 
SHP-2 99 showed major defects in development and haematopoiesis.   
 
1.9 Apoptotic Cell Clearance Mechanisms 
Apoptotic cells must be cleared from the system to potentially avoid secondary 
necrosis and leakage of intracellular contents, which could have harmful 
consequences to the body with the development of autoantigens and disease, such as 
SLE (systemic lupus erythematosus).  The apoptotic cell is recognised by 
macrophages engaging cellular receptors, which mediate the tethering and eventual 
engulfment of the apoptotic cell 100.   
 
CD14 originally identified as the LPS receptor 101, is involved in the recognition of 
apoptotic cells by macrophages.  This molecular interaction stimulates the production 
of the inflammatory cytokine TNFα.  The interaction of apoptotic leukocytes with 
macrophages mediated by CD14 does not stimulate an inflammatory response 102.  A 
study with CD14KO mice revealed the persistence of apoptotic cells, and a decreased 
interaction between the leukocyte and the macrophage when compared with wild 






apoptotic cells, which suggested CD14 does not contribute to autoimmunity, but is 
required for the efficient clearance of apoptotic leukocytes 103. 
 
Other apoptotic cell recognition molecules include CD36 binding to thrombospondin 
(TSP) which acts as a ‘molecular bridge’ between CD36 and αvβ3 integrin on the 
macrophage, and the receptor on the apoptotic leukocyte 104.  A study with apoptotic 
fibroblasts showed TSP was released from the apoptotic cell and acted as a 
chemoattractant to macrophages, and was also capable of binding to CD36 on the 
apoptotic cell.  This complex was recognised by the CD36/αvβ3/TSP on the 
macrophage, which led to the clearance of the apoptotic fibroblast 105. 
 
Complement also plays a role in the clearance of apoptotic cells, specifically the C1q 
component.  Studies with C1qKO mice demonstrate impaired clearance of apoptotic 
cells in a model of SLE.  HMDM from C1q-deficient individuals also showed 
impaired phagocytic clearance 106.  Mannose-binding lectin (MBL) was also shown 
to bind to apoptotic cells, and with Clq bind to calreticulin on the macrophage.  
Calreticulin associates with CD91 to mediate uptake of apoptotic cells 107. 
 
Stable phosphatidylserine (PS) exposure on the surface of apoptotic cells has been 
shown to mediate cellular uptake by macrophages 108.  On the surface of viable cells, 
the zwitterionic phospholipids phosphatidylcholine (PC) and sphingomyelin are 






phosphatidylethanolamine (PE) are expressed.  The ‘flip-flop’ of PS from the outer 
membrane to the inner leaflet is maintained by aminophospholipids translocase 109.  
When the cell undergoes apoptosis, this enzyme is inactivated, whereas a scramblase 
is activated resulting in stable expression of PS upon the cell surface 110.  Tethering 
of apoptotic cells to macrophages by receptor ligation has been shown to require PS-
receptor interaction for engulfment 111.  A protein secreted by activated 
thioglycollate-elicited macrophages, milk fat globule epidermal growth factor-8 
(MFG-E8) has been shown to bind to PS on the surface of apoptotic cells and 
enhance their uptake 112.   
There is some controversy surrounding the receptor for PS (PSR), which was initially 
cloned in 2000 113 suggesting PSR on macrophages recognises PS exposure on the 
surface of apoptotic cells.  Generation of a PSRKO mouse was embryonic lethal and 
demonstrated uncleared apoptotic cell corpses in a variety of tissues.  PSR-deficient 
macrophages also showed impaired phagocytosis of apoptotic cells 114.  However, 
although recent data has shown that ablating PSR in mice lead to development 
defects and embryonic lethality, the mutation had no defect in apoptotic cell 
clearance.  PSRKO macrophages were able to phagocytose apoptotic cells in a 
variety of tissues, which suggested PSR is not involved in apoptotic cell clearance 
during development 115.   
 
ABCA1 (ATP-binding cassette 1) expression was found in the developing murine 
embryo localised in areas of apoptotic cell death.  ABCA1 is a molecule expressed 






116.  ABCA1KO mice developed immune-complex induced glomerulonephritis, 
which was due to a defect in apoptotic cell clearance 117.   
 
The scavenger receptor B1 (SR-B1) has a similar ligand binding affinity to CD36 for 
high density lipoprotein, and was shown to be a receptor for apoptotic thymocytes 
118.  SR-B1 was shown to be the receptor for PS on non-professional phagocytes, in a 
study of the clearance of thymocytes by thymic nursing cells (TNC), SR-B1 was 
found to mediate the uptake of apoptotic thymocytes into the TNC 119.  Sertoli cells 
in murine testicles phagocytose apoptotic spermatozoa via SR-B1 binding to PS, and 
provide another mechanism by which ‘amateur’ phagocytes engulf apoptotic cells 
120.   
 
1.10 Hypothesis and Aims 
The hypothesis underlying the work presented in this thesis is; the differential 
recruitment of signalling and adapter molecules to the cytoplasmic domain of CD31 
in viable and apoptotic leukocytes, results in the tethering of apoptotic cells and the 
escape of viable cells.  A difference in recruitment of signalling and adapter 
molecules may mediate the detachment of the viable cell from macrophages, and 
cause the apoptotic cell to remain attached, thus facilitating engulfment.   
This work attempts to dissect the mechanism by which CD31 signals in viable and 




















2.1  Introduction 
2.1.1 CD31 and Diapedesis   
It is well established that CD31 has a critical role in the migration of leukocytes 
during diapedesis 5.  Recently, CD31 has been shown to localise to sub-cellular 
compartments in the endothelial cell membrane during leukocyte migration.  As the 
leukocyte transmigrates, CD31 is recycled along the endothelial barrier, with high 
levels of expression of CD31 juxtaposed to the leukocyte, right through the process 
of migration 13. Studies with human neutrophils migrating through a HUVEC 
monolayer showed that CD31 aligned migration in the direction of fluid flow, and 
that migration was accelerated through the endothelial cell layer, suggesting that 
CD31 plays a critical role in mediating the direction and velocity of leukocyte 
migration 121. 
 
2.1.2 Integrin Activation and CD31  
CD31 contributes to the process of migration of T cells acting as an adhesion 
amplifier, upregulating β1 integrins during adhesion of the T cell to the endothelium.  
Homophilic CD31 interactions thus increase the adhesion of the T cell by promoting 
firm adhesion that facilitates transendothelial migration 4. Ligation of CD31 on NK 
cells has also been shown to upregulate β2 integrins during extravasation into 
inflamed tissues 7.  The recruitment of neutrophils to sites of inflammation is also 
facilitated by CD31, principally via the upregulation of α6β1 integrin surface 






membrane 6.  Thus, CD31 works in concert with integrins during the process of 
leukocyte transmigration to sites of inflammation. 
 
2.1.3 CD31 and Cell Migration 
Endothelial CD31 also has a critical role in the process of angiogenesis, the growth 
of new blood vessels. Angiogenesis is a complex process involving capillary 
endothelial cells detaching, migrating to the new site, reforming cell-cell contacts 
and proliferating to form new endothelial layers.  CD31 participates in the later 
stages of this process by forming tight cell-cell contacts giving rise to a cobblestone 
cell monolayer appearance.  Furthermore, in an in vitro three-dimensional model of 
murine angiogenesis, tube formation was reduced by the addition of monoclonal 
antibodies against CD31 122. 
A regulatory function for CD31 was also found in wound healing migration 
experiments where cell monolayers were physically disrupted and cell migration into 
the wound was then quantified.  NIH/3T3 cells normally null for CD31 expression, 
were transfected with full length, or CD31 missing the cytoplasmic domain and 
wound healing migration was then assayed.  Migration was found to be impaired in 
the cells transfected with full length CD31 when compared with those transfected 










2.1.4 Role of the ITIM in Migration-For or Against? 
Consistent with the evidence that CD31 is intimately involved in endothelial cell 
migration, wound-induced migration was impaired in REN (mesothelioma) cells 
transfected with CD31 missing the ITIM tyrosines, compared with REN cells 
transfected with full length CD31. SHP-2 requires intact ITIM tyrosines to bind to 
CD31, and the loss of these tyrosines, and consequently of SHP-2 binding resulted in 
decreased cell migration.  SHP-2 is thought to be brought closer to the membrane in 
order to facilitate focal adhesion turnover, or be sequestered away to allow FAK to 
act in the later stages of focal adhesion maturation  59. However, there is some 
conflicting evidence as to the role of the ITIM in CD31 migration and motility.    
Wild-type CD31 was also found to be essential for mediating endothelioma cell 
migration; however in contrast to the findings with REN cells, the ITIM was found to 
act as a constraint to negatively regulate migration.  Transfection with an ITIM 
mutant resulted in an increase in β-catenin phosphorylation, which could potentially 
loosen adherens junctions; and an increase in FAK phosphorylation, which is 
important for regulation of focal adhesion turnovers.  In this system, an imbalance 
between Rac and Rho was found in CD31 knock-out cells, which increased single 
cell motility, but impaired co-ordinated wound healing motility 60.   Although this 
finding contrasts those for REN cells, CD31 clearly has the potential to regulate 









2.1.5  CD31 and Cellular Detachment 
Macrophage recognition and ingestion of dying cells in vivo, is essential to protect 
from the potentially deleterious effects of toxic intracellular contents.  Results from 
in vitro studies have shown that many different molecular pathways may contribute 
to interaction of macrophages with apoptotic cells124.  Whilst a role for homotypic 
CD31 interaction in macrophages binding to both viable and apoptotic leukocytes 
might be expected, previous work from this laboratory demonstrated a novel role for 
CD31 in active viable leukocyte detachment from the macrophage surface.  The 
experimental system exploited temperature-dependent differences in cell adhesion.  
Viable or apoptotic cells bound to macrophages at 20˚C were subsequently allowed 
to detach under flow at either 20˚C or 37˚C.  In contrast to viable cells, which 
exhibited temperature dependent detachment at 37˚C, apoptotic cells remained 
attached. It was postulated that viable cells were able to transmit signals via CD31 to 
engage the cell’s motor machinery and escape, whilst in the apoptotic cell signalling 
was disabled, and the cells were incapable of detaching 84.   
 
2.1.6 Experimental Aims 
An in vitro static detachment assay was developed as a model of leukocyte-
macrophage interactions based on preliminary experiments (Dr Simon Brown, 
University of Edinburgh UK, personal communication).  The myelomonocytic cell 
line THP-1 was used following differentiation into a ‘macrophage-like’ phenotype 
with PMA (phorbol 12 myristate 13-acetate).  Undifferentiated cells grow in 
suspension, upon differentiation; the cells become adherent and show similar 






used for studies involving macrophage models of disease such as atherosclerosis 125.  
The differentiated THP-1, hence termed THP-1, were plated into 8 well glass 
chamber slides to allow ease of handling, and differentiation into a monolayer was 
observed after 5 days culture.  Seven wells of cells were stained with cell tracker 
orange under serum-free conditions at room temperature.  One well of cells was left 
unstained to act as a negative control during flow cytometry analysis.  Excess stain 
was then well washed off with media containing serum and replaced with fresh 
complete media.  Simultaneously, the test leukocytes were stained with cell tracker 
green also under serum free conditions, with a population from the same flask left 
unstained as a negative control.  Excess stain was washed off with complete media 
and replaced with fresh.  The populations of leukocytes used were at 75% or above 
viability, as confirmed by annexin V and propidium iodide staining under flow 
cytometric analysis.  
One million of the test stained leukocytes were added to the THP-1 in 6 of the wells 
and allowed to settle for 15 minutes at room temperature.  Room temperature was 
chosen to allow initial tethering to occur at a temperature where cytoskeletal 
reorganisation was inhibited84.  The chamber slide was then placed into a media bath 
either at room temperature, or at 37˚C, and inverted for 30 minutes.  The chamber 
slide was then turned right side up and removed from the media bath.  The media 
was then gently removed and trypsin/EDTA was added for 15 minutes to remove the 
cells.  The cells were then resuspended in FACS buffer for flow cytometric analysis.  
Results are expressed as the number of leukocytes still attached after inversion per 






The aim of the experiments shown in this chapter was to investigate the role of CD31 
in viable leukocyte detachment from macrophages.  A number of CD31-expressing 
cell lines were used initially to determine whether CD31 mediated detachment of 
viable cells represented a general phenomenon.  The suspension T cell line Jurkats 
were used with stable transfection of CD31 with altered ITIM motifs to assess the 
contribution of cytoplasmic sequences within CD31 in regulating viable cell 
detachment. 
Experiments were performed in triplicate and shown as the mean ±SD.  Statistical 
tests used were t-test (two samples) or one way ANOVA (three or more samples) 







2.2.1 CD31 Positive and CD31 Negative Jurkat Attachment 
The attachment assay (Figure 2.2:1) with settling at room temperature and inversion 
at 37˚C was performed with CD31 negative and CD31 positive Jurkats, stably 
transfected to express CD31.  A representative FACS dot plot shows two cell  
populations from a well by forward and side scatter (Figure 2.2:2 panel A).  The 
Jurkats were then gated on their fluorescence as measured through the FL-1 channel 
(B), and the THP-1 gated on their fluorescence as measured through FL-2 (C).   
More CD31 negative Jurkats remained attached to the THP-1 than CD31 positive 
Jurkats (Figure 2.2:3) (n=3, p=0.117), showing that CD31 mediates the detachment 
of  viable CD31 positive Jurkats, validating the assay and thus supporting previous 












Figure 2.2:1.  Model of leukocyte-macrophage interactions was developed.  THP-1 are 
differentiated with PMA over 5 days onto 8 well chamber slides and stained with cell 
tracker orange.  Leukocytes were stained with cell tracker green, and added to the 
THP-1 monolayer.  After a 15 minute settling period, the chamber slide was immersed 
in a media bath and viable cells were allowed to detach under gravity for 30 minutes.  
The chamber slide was treated with trypsin-EDTA and the cells were analysed by flow 
cytometry. The results are expressed at number of leukocytes remaining bound per 
100 THP-1 cells counted. Jurkats were assayed for viability by annexin V and 









Figure 2.2:2.  Representative FACS dot plot showing the end point of the attachment 
assay.  Jurkats stained cell tracker green appear in the FL-1 channel, and the THP-1 
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Figure 2.2:3.  More CD31 negative Jurkats remain attached to the THP-1 than CD31 























2.2.2 Leukaemic Cell Line Attachment Assay 
To determine if the CD31-dependent detachment from THP-1 was particular to 
stably transfected Jurkats, the standard attachment assay (with settling at room 
temperature and inversion at 37˚C) was utilised to assess a panel of leukemic cell 
lines.  This included CD31 negative Jurkat T cells, CD31 positive Jurkats, U937, 
KG-1 and MM6 which all grow as a non-adherent suspension culture. 
The Jurkats have been previously stably transfected with CD31 wild-type 2.  U937 
are a monocytic leukaemia with CEACAM (CD66) surface expression 126,127.  MM6 
(mono-mac 6) cells are a monocytic-like cells that express CD13, CD15, CD34, 
CD68 and HLA-DR and are negative for CD3, CD4, CD14, CD19 and CD33 128.  
KG-1 cells were established as an acute myelogenous leukaemia, of granulocytic 
phenotype that grows in suspension and expresses HLA-A30 and HLA-B35 129.  
Importantly, KG-1 cells do not express the SH2 domain containing phosphatase 
SHP-1 (Dr Isabelle Heinisch, University of Edinburgh, UK, personal 
communication). 
Examination of CD31 surface expression by flow cytometry revealed all cell lines 
express CD31 (Figure 2.2:4), KG-1 and MM6 exhibited greater fluorescence as 
compared with isotype controls, suggesting higher overall CD31 surface expression.  
The standard attachment assay showed that the U937 cells exhibited greatest 
attachment to the THP-1 compared with CD31 positive Jurkats, KG-1 and MM6 
cells (Figure 2.2:5) (n=3, p=0.001).  The KG-1 and MM6 cell line showed 







Figure 2.2:4.  Expression of CD31 on different cell lines. FITC conjugated CD31 mouse 
anti-human was used to label the different leukemic cells lines and binding assessed 
by flow cytometry.  Controls included unstained cells and an isotype control of mouse 
IgG1-FITC. All cell lines, with the exception of CD31 negative Jurkats, express CD31 on 
their surface relative to isotype control IgG1 binding. 





























































































Figure 2.2:5.  U937 exhibit the most attachment to the THP-1 than CD31 positive 






























2.2.3 Leukaemic Cell Line Room Temperature Detachment Assay 
Although the initial experiments show the leukemic cell lines capable of interacting 
with the THP-1, and of note the dependence of the Jurkats on CD31 to mediate this 
interaction, the initial numbers of cells tethered at room temperature was not 
measured.  The number of cells binding at the room temperature settling step 
provides information relating to the ability of the leukemic cell to interact with the 
THP-1, and therefore to detach at 37˚C.  To overcome this and provide an indication 
of the initial interaction between the leukocyte and the THP-1, the detachment assay 
was carried out with all steps at 20˚C, including the inversion step where gravity 
provides the detaching force. 
Comparison between the standard assay and the room temperature assay showed 
U937 exhibited low levels of attachment at 20˚C and increased attachment at 37˚C, 
(Figure 2.2:6) (n=3, p=0.093) suggesting that raising the temperature promotes the 
adhesion of the cells to the THP-1. However, the standard and room temperature 
assay revealed similar levels of attachment of MM6 cells under both conditions 
(Figure 2.2:7) (n=3, p=0.574).  KG-1 cells also show similar levels of attachment 
with the standard and room temperature assay (Figure 2.2:8) (n=3, p=0.2951), 
suggesting that the temperature of the assay does not affect the ability of the 
leukocyte to adhere to the THP-1. 
The initial tethering at room temperature of CD31 positive Jurkats was compared 
with the standard assay (Figure 2.2:9).  The CD31 positive Jurkats were found to 






84.  CD31 negative Jurkats do not exhibit this temperature-dependent effect (Figure 
2.2:10), implying the alternative attachment mechanisms allowing adhesion of the 

















Figure 2.2:6.  U937 exhibit lower levels of attachment at room temperature, compared 










Figure 2.2:7. MM6 show similar levels of attachment at room temperature and under 









MM6 20˚C MM6 37˚C
Number of 








Number of cells 


















Figure 2.2:8.   KG-1 show similar levels of attachment at room temperature and under 














Figure 2.2:9.  Attachment of CD31 positive Jurkats is increased at room temperature 
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Figure 2.2:10.  Attachment of CD31 negative Jurkats at room temperature is similar to 
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2.2.4 ITIM Mutant Jurkat Attachment 
Stable cell lines of CD31 transfected Jurkats with mutations in the cytoplasmic 
domain at ITIM tyrosines 663 (Y663F), 686 (Y686F) and both 663 and 686 
(Y663F/Y686F)2 were also used as the target leukocyte to examine the potential 
effect of tyrosine phosphorylation of the cytoplasmic domain of CD31 in mediating 
detachment signals (Figure 2.2:11) (n=3, p=0.0431). Using the standard assay, 
Y663F Jurkats showed similar levels of attachment to THP-1 as the wild-type CD31 
positive Jurkats.  Tyrosine 663 has previously been shown to be important for SHP-2 
activation, whereas tyrosine 686 is important for binding of SHP-2, so with the 
Y663F point mutant, SHP-2 was still able to bind, and potentially bind downstream 
effectors participating in downstream signalling.  Y686F Jurkats exhibited slightly 
more attachment to the THP-1 than wild-type or Y663F Jurkats.  However, the 
greatest effect was observed with the Y663F/Y686F double mutant, which showed 
the greatest attachment.  This finding therefore demonstrates the ITIM is essential for 
mediating detachment of viable leukocytes from macrophages, as without the ITIM, 














Figure 2.2:11.  Y663F/Y686F Jurkats exhibited the greatest level of attachment to the 




























2.2.5 Temperature Dependent ITIM Mutant Jurkat Attachment Assay 
As a temperature dependent attachment was demonstrated by CD31 positive wild-
type expressing Jurkats, performing the assay with ITIM mutant Jurkats and all steps 
at room temperature may dissect the downstream signalling pathway involved in 
maintaining cellular attachment.  
A temperature dependent effect was observed with Y663F mutant Jurkats, similar to 
the effect observed with wild type CD31 expressing Jurkats. With the room 
temperature assay, more cells bound to the THP-1 monolayer when compared with 
the standard assay.  This observation demonstrated that subsequent detachment under 
gravity was likely to be independent of SHP-1 binding to CD31, as SHP-1 binding to 
CD31 requires the presence of both ITIM tyrosines (Figure 2.2:12) (n=3, p=0.021).  
With Y686F mutant Jurkats, there was little difference in attachment between the 
room temperature and standard assay (Figure 2.2:13) (n=3, p=0.516), which implies 
Jurkat detachment requires SHP-2 binding to CD31, as SHP-2 binding is dependent 
on intact tyrosine 686.  Attachment of Y663F/Y686F mutant Jurkats was also similar 
between the room temperature and standard assay (Figure 2.2:14) (n=3, p=0.875), 
supporting the notion that the ITIM tyrosines and binding partners are required as 















Figure 2.2:12.  Y663F mutant Jurkats exhibit temperature dependent attachment to the 












Figure 2.2:13.  Y686F mutant Jurkats exhibit similar levels of attachment compared 
between room temperature and standard assay showing tyrosine 686 is required for 
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Figure 2.2:14.  Y663F/Y686F Jurkats show similar levels of attachment to the THP-1 
compared between room temperature and standard assay (p=0.8746, n=3), implying a 
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2.2.6 Stibogluconate Treatment of CD31 Positive Jurkats  
SHP-1 and SHP-2 phosphatases have both been shown to bind to the cytoplasmic 
domain of CD31 57,130.  To directly examine the role of SH2 phosphatases in 
detachment, and specifically the activation and role of the phosphatase domain, 
CD31 wild-type Jurkats were treated with sodium stibogluconate, a drug used in the 
treatment of leishmaniasis which inhibits only the catalytic activity of the 
phosphatases, but not their binding to CD31.  Sodium stibogluconate inhibits SHP-1, 
SHP-2 and PTP1B. Previous studies indicate that at 10µg/ml, only SHP-1 will be 
targeted 131. In this series of experiments, all assays were performed under standard 
conditions, with room temperature settling and inversion at 37˚C.  Drug treatment 
did not affect the cell viability as assayed by annexin V/propidium iodide staining as 
described in Materials and Methods.  Treatment with 10µg/ml sodium stibogluconate 
gave somewhat variable results.  However there was little difference in attachment of 
stibogluconate treated cells compared with untreated Jurkats (Figure 2.2:15) (n=5, 
p=0.636).  At higher concentrations of stibogluconate (100µg/ml), SHP-2 has been 
shown to be inhibited 131.  Treatment of Jurkats with this higher concentration did not 
affect the attachment, although again there was the same inconsistency in the results 















Figure 2.2:15.  Stibogluconate treated CD31 positive Jurkats (10μg/ml) attachment 





Figure 2.2:16.  100µg/ml stibogluconate treatment of CD31 positive Jurkats does not 
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2.2.7 siRNA Knock-Down of SHP-2 in Jurkats 
RNA interference introduces double-stranded RNA into cells that is cleaved by Dicer 
into short 21 nucleotide sequences with an overhang of 2 bases at the 3’ end.  One 
strand of RNA is recognised by the RISC (RNA-induced silencing complex) and 
used to target the homologous sequence from the genome, thus targeting both for 
destruction by nuclease activity 132.  To target SHP-2, suspected as being involved in 
mediating detachment signals, for knock-down in Jurkats short-hairpin RNA 
(shRNA) constructs were generated for delivery into the cell by lentivirus. 
As a pharmacological approach had been unsuccessful, a different approach to target 
SHP-2 was required. As SHP-2 is expressed in Jurkats, using siRNA to knock down 
SHP-2 expression could prevent the positive signalling through CD31, and therefore 
prevent detachment from macrophages. A SHP-2 sequence previously used to 
achieve knockdown in fibroblasts 133 was commercially produced (Dharmacon) and 
transfected into CD31 positive Jurkats by Amaxa electroporation. As a positive 
control a lamin A/C sequence produced by Dharmacon was used.   The cells were 
harvested at 24, 48 and 72 hours post-transfection, lysed and assessed for protein 
expression of either SHP-2 or lamin A/C.  There was a slight decrease in SHP-2 
expression at 72 hours post-transfection observed with this method (Figure 2.2:17).  
Western blotting for lamin A/C also showed there to be some decrease in lamin A/C 
protein levels at 72 hours (Figure 2.2:18) (See Appendix for transfection 
troubleshooting). However, the decrease in protein expression observed was deemed 
insufficient to assess the effects of SHP-2 knockdown upon the ability of the Jurkat 






sought.  As electroporation induces cell death, lipid mediators were used.  Both 
EPOCH and Dharmacon transfection reagents were used, but with no knock-down of 











Figure 2.2:17.  CD31 positive Jurkats transfected by Amaxa electroporation, untreated 
cells, electroporation only, SHP-2 RNA, or lamin A/C RNA were harvested at 24, 48 and 








Figure 2.2:18.  CD31 positive Jurkats transfected by Amaxa electroporation, untreated 
cells, electroporation only, SHP-2 RNA or lamin A/C RNA, harvested at 24, 48 and 72 




























































2.2.8 Lentiviral Transduction  
Lentiviruses are a genus of the Retroviridae family, of which HIV-1 (human 
immunodeficiency virus-1) is a species utilised in the development of this 
technology.  The viruses carry their genome as double-stranded sense RNA, and are 
capable of transcribing it to DNA once inside a cell.  The virus particle contains 
reverse transcriptase, integrase and protease.  The virus is surrounded by an envelope 
of host cell membrane, with the glycoprotein the only viral protein expressed on the 
surface.  This glycoprotein interacts with the host cell surface proteins in order to 
infect the cell.   
The genome contains gag, pro, pol and env genes required for virus replication.  gag 
encodes the structural proteins, pro the protease required for cleaving gag and gag-
pol  and particle maturation, pol the reverse transcriptase and integrase required for 
transcription to DNA and integration into the host genome, and env encodes the 
glycoprotein expressed on the surface of the virion.  Lentiviruses also encode 
accessory genes that regulate infectivity and replication.134  
To infect a host cell, the virus binds to its receptor via the envelope glycoprotein, 
allowing fusion of the cell membranes and the introduction of the uncoated virus into 
the cytoplasm.  The viral genome is then transported to the nucleus via the cell’s 
nuclear transport system.  The viral genome is reverse transcribed to DNA where it is 

















Figure 2.2:19 Retrovirus infection and replication cycle showing viral genome reverse 






2.2.9 Packaging and Transduction 
Once the insert of interest is cloned into the lentiviral vector, it is then ready to be 
packaged into virus particles.  Third generation lentivirus vectors have been 
developed that have much reduced capacity of producing virions infective to 
workers, thus improving the biosafety.  Two plasmids one containing the transgene 
and the other containing gag, pol and env (VSV-G env is used as it has a broad host 
range and can withstand concentration by ultracentrifugation) are transfected into the 
packaging cell line HEK 293T, developed from human embryonic kidney cells 
transfected with adenovirus E1 that activate the CMV promoter present in the 
transgene plasmid resulting in greater virus titre.  HEK 293T cells are adherent and 
produce virus into the supernatant which can be harvested, and concentrated if 
desired 135.  The virus particles contain the transgene of interest and this can now be 
used to transduce the cells required.  
 
2.2.10 Proof of Concept Lentiviral Transductions 
CD31 positive Jurkats were transfected with a GFP EIAV (equine infectious anaemia 
virus) vector.  The cells were then incubated under normal cell culture conditions for 
48hrs before examination of GFP expression using a fluorescence microscope.  The 
cells were transduced with nearly 100% efficiency (Figure 2.2:20).  Jurkats were also 
transduced with pLenti Lac-Z, cells were incubated under normal cell culture 
conditions for 72 hours then stained with X-gal staining solution (as described in 
Materials and Methods) for a minimum of 3 hours before visualising under light 
microscopy show the cells can be transduced, albeit with a low efficiency (Figure 






In view of these encouraging preliminary experiments that demonstrate the cells are 
able to be transduced, an siRNA construct for SHP-2 could be engineered into this 
















Figure 2.2:20.  Transduction of CD31 positive Jurkats with EIAV-GFP lentivirus 






Figure 2.2:21.  Transduction of CD31 positive Jurkats with Lac-Z-lentivirus at 48hours 
post transduction show the cells can be transduced but at low transduction 













To study the role of CD31 in mediating viable leukocyte detachment from 
macrophages 84, a static assay was developed with the macrophage-like cell line 
THP-1, and leukemic cell lines U937, MM6, KG-1 and Jurkats stably transfected 
with CD31.  This assay, in which cells were allowed to attach at 20°C and then 
detach at 37°C, revealed that there were low levels of binding of CD31 positive 
Jurkats and MM6 to the THP-1, whereas the U937 and KG-1 exhibited greater levels 
of binding.  However, since this assay only quantified the cells that remained bound 
after inversion at 37˚C, it did not provide information relating to the initial binding 
signal when the chamber slide was incubated at 20°C, thus the assay was repeated 
with all steps at 20°C and compared with results when inversion was performed at 
37°C. In previous studies, a difference in the number of cells bound would indicate a 
temperature dependent attachment effect. 
MM6 cells did not exhibit temperature dependent attachment to THP-1.  These cells 
have been shown to express CD38, which is a ligand for CD31.  A study with MM6 
showed that the CD31-CD38 interaction could be important for MM6 extravasation 
to sites of inflammation 136.  As THP-1 also express CD38, it could be that during the 
attachment assay, the MM6 are interacting with the THP-1 in a CD31-CD38 manner, 
which may not act to regulate adhesion in a temperature dependent way as suggested 
for homophilic CD31 interactions. 
KG-1 cells also do not exhibit temperature dependent attachment when the inversion 






differentiated dendritic cells (DC) 137, so the interaction observed here may be more 
similar to that of an immature DC and a macrophage.  In situ, interaction between 
immature DCs and macrophages in lymph nodes will be predisposed to be adhesive 
to allow communication of antigen and subsequent macrophage-induced maturation 
of the DC.  So it is possibly more likely that the readily reversible adhesions required 
for observation of cellular detachment are more difficult to detect using KG-1 cells.  
Monocytic–like U937 also do not exhibit temperature dependent attachment, in fact 
the cells became more adherent when the temperature was raised. It has previously 
been shown that U937 engage CD31 predominantly via αvβ3 in a heterotypic 
interaction together with a low level of homophilic CD31 binding.  The study also 
showed a temperature-dependent adhesion (temperature range 37-4˚C) of the U937 
to CD31 extracellular domain construct 9.  With the static attachment assay used here 
(temperature range 37-20˚C), we have shown a similar result, with more U937 
adhering at 37˚C than at the lower temperature. This interaction may lead to a 
different signalling pathway in the U937 mediated by the integrin and not through 
CD31, which could lead to a more adhesive response through integrin activation.   
In order to investigate the adhesive mechanisms described by the leukemic cell lines 
U937, KG-1 and MM6 further, antibody blocking studies could be used.  Blocking 
the homophilic interaction of CD31 using monoclonal antibodies before performing 
the attachment assay may then shed light upon the involvement other molecules such 
as integrins.   
CD31 negative Jurkats also were unable to exhibit temperature-dependent 






binding of Jurkats to THP-1 that is not temperature-sensitive.  One unlikely 
possibility was that the population of cells that remain attached may not be viable, 
and could represent the apoptotic and necrotic cells in the culture.  The differences 
observed between CD31 positive and CD31 negative Jurkats, and again with the 
Y663F/Y686F mutant Jurkats when compared with CD31 positive Jurkats could 
have been due to the different levels of death in these populations.  However, as each 
cell population was growing well and had the levels of apoptosis and necrosis 
measured at each assay.  The cells were found to be mostly viable, and the 
differences between each population was minimal, we were confident the differences 
in attachment were due to the properties of CD31, not due to differences in cell 
viability.  Moreover, to overcome this, the population of cells could be depleted of 
PS expressing cells prior to the assay to remove apoptotic populations. This may 
have ‘fine tuned’ the assay and possibly improved the error between each assay.  
Alternatively, the temperature-insensitive binding could be due to firmer integrin-
mediated adhesion, with CD31 on the THP-1 engaging β1 integrins 138 on the Jurkat 
in the absence of CD31. 
Jurkats stably transfected with full-length wild type CD31 exhibited less attachment 
to the THP-1 monolayer than CD31 negative Jurkats.  This finding recapitulates 
previous work that CD31 mediates a detachment signal in the viable leukocyte 84, 
and prompted questions about which signalling and adapter molecules were binding 
to the cytoplasmic domain and how they were acting to drive the cell’s motor 
machinery.  SIRPα, an immunoglobulin superfamily member, binds SHP-2 via its 






leading to MAPK activation and migration 139. It is therefore conceivable that CD31, 
which is an immunoglobulin superfamily member containing an ITIM could engage 
similar signalling pathway following binding that would result in increased cell 
migration. 
 
Utilising Jurkats provided a model leukocyte that could be genetically modified with 
mutations to the cytoplasmic domain of CD31 at key tyrosine residues 663 and 686 
59.  CD31 positive Jurkats with mutations in ITIM tyrosines 663, 686 and both 663 
and 686 were used as viable leukocytes in the attachment assay.  Only the 
Y663F/Y686F mutant Jurkat showed increased attachment when compared with 
CD31 wild-type and with the single Y663F and Y686F mutants.  This observation 
suggests that the ITIM was essential for mediating the signals required for leukocyte 
detachment, and that mutating single tyrosines on their own did not have this effect.  
One implication of these data is that the signalling and adapter molecules are able to 
bind to either of the tyrosines present in the cytoplasmic domain.  The SH2 domain 
containing phosphatase SHP-2 has been shown to bind to CD31 and transduce 
motility signals through binding to the ITIM tyrosines59. 
 
The assay was repeated at room temperature to assess initial binding of the Jurkats to 
the THP-1.  Y663F mutant Jurkats were also found to exhibit temperature dependent 
attachment; since SHP-2 requires tyrosine residue 686 on CD31 for binding.  SHP-2 
is still able to bind to tyrosine 686 independently of tyrosine 663. Detachment may 






to require tyrosine 663 60.  In contrast, the Y686F mutant did not show temperature 
dependent attachment. One interpretation of this data is that SHP-2 is unable to bind 
to the cytoplasmic domain of CD31 and provide a docking site for downstream 
signalling molecules.  The Y663F/Y686F mutant Jurkat also does not show 
temperature dependent attachment, again recapitulating previous work in this 
laboratory 84, and strongly suggests that in the absence of the cytoplasmic ITIM 
motif, CD31-mediated motility is disabled. 
As SHP-2 is able to bind to the ITIM of CD31, it is conceivable that the regulation of 
adhesion is initiated by SHP-2 acting as a docking protein. SHP-2 binding would be 
predicted to influence downstream signalling following this interaction.  If SHP-2 
was unable to bind to the cytoplasmic domain of CD31 because of mutation of the 
ITIM, the signalling pathway leading to disruption of adhesions may not occur, 
which could explain why the Y663F/Y686F Jurkat exhibited impaired detachment. 
 
To explore the possibility of SH-2 domain containing phosphatases binding to the 
cytoplasmic domain of CD31 and exerting their catalytic activity by 
dephosphorylating substrates involved in downstream signalling, CD31 positive 
Jurkats were treated with the anti-leishmaniasis drug sodium stibogluconate.  The 
drug specifically inhibits the catalytic activity of SHP-1 and SHP-2 and the inhibition 
does not require the SH-2 domain or C-terminal region.  At a concentration of 
10µg/ml SHP-1 catalytic activity is specifically inhibited, whereas at 100µg/ml SHP-
2 activity is also inhibited.  At both concentrations there was no difference in the 






suggested the catalytic activity of SHP-1 and SHP-2 was not necessary for mediating 
downstream detachment signals.   
One caveat to these experiments is that the efficiency of the drug treatment was not 
measured by assessing SHP-1 or SHP-2 phosphatase activity within the treated cells.  
There was some variability in the effects of stibogluconate treatment upon cell 
attachment.  One possibility is that stibogluconate did not achieve consistent 
phosphatase inhibition.  Further experiments would be necessary to test this 
possibility, for example using a range of stibogluconate concentrations and then 
measuring the activity of the phosphatases by phosphatase assay. 
SH-2 domain containing phosphatases have been shown to have a critical role in 
signalling during cell migration.  SHP-2 is involved in integrin-mediated adhesive 
signals.  Fibroblasts negative for SHP-2 exhibited decreased ability to migrate and 
spread.  This adhesion defect was rescued upon transfection of the fibroblasts with 
wild-type SHP-2.  In focal adhesions, FAK and SHP-2 may work concurrently, with 
SHP-2 phosphatase activity deactivating FAK and thus allowing FAK regeneration 
and focal adhesion turnover throughout the process of cell migration 140.  A catalytic 
mutant of SHP-2 expressed in human carcinoma acted to reduce integrin-mediated 
activation of MAPK and consequently cell spreading.  Consistent with this 
observation, neutralising SHP-2 activity decreases migration and is associated with 
an increase in formation of stable focal adhesion contacts 141.   
Transfecting CHO cells with a catalytic mutant of SHP-2 were demonstrated to alter 
the cell morphology and reduced cell polarity.  Transfected cells had increased 






act to regulate focal adhesion turnover by dephosphorylating tyrosine phosphorylated 
substrates, and disruption of this activity by mutation may inhibit the disassembly of 
established focal contacts.  Thus, recruitment of SHP-2 to focal adhesions may 
represent a mechanism for monitoring focal adhesion events and controlling the 
strength of adhesion to allow the cell to migrate 142.  
 
SHP-2 has been shown to be involved in signalling pathways through receptor 
tyrosine kinases, such as Met, and has the ability to serve as a docking protein for 
Gab1.  Met becomes phosphorylated and binds Gab1 on a specific tyrosine residue.  
Gab1 itself becomes tyrosine phosphorylated and provides binding sites for other 
downstream signalling molecules, including SHP-2 143.  Gab1 is then able to bind the 
SH-2 domain of Crk II.  This molecule binds to DOCK180 which together with 
ELMO acts as an guanidine exchange factor for Rac, leading to activation.  Activated 
Rac has been shown to destabilise adherens junctions in MDCK cells 144.     
 
In order to probe the role of SHP-2 in detachment we attempted to knock-down SHP-
2 expression in CD31 positive Jurkats to examine the effect of this on the ability of 
the Jurkat to attach to the THP-1. Various methods of transfection of SHP-2 siRNA 
were attempted including electroporation and lipid mediators all without success. 
Electroporation resulted in a reduction in viable cell number and low transfection 
efficiency, whereas lipid mediators failed to increase transfection efficiency despite 







As an alternative approach, retrovirus technology could be used to introduce the 
RNA into the cell.  In particular, lentiviral plasmids have been developed to enable 
cloning of the sequence of interest into this system and transfected along with the 
vector containing the genes for virus replication, which by homologous 
recombination generates a vector with the sequence of interest plus the ability to 
make virus.  This vector is then transfected into a packaging cell line, allowing 
production of virus containing short hairpin RNA (shRNA).  When this virus is then 
transfected into the cell line of interest the shRNA is transcribed and is recognised by 
Dicer, an RNAse that cleaves the hairpin into small 21-23 nucleotide fragments; 
these are the small interfering RNAs (siRNA).  The siRNAs are incorporated into the 
RISC complex, which unwinds and then guides the siRNA to its complementary 
mRNA.  The endogenous mRNA is then destroyed and translation of the protein 
does not occur 145.   
Due to the complexity of designing and engineering the siRNA constructs, time 
constraints precluded our ability to use these constructs experimentally.  However, if 
the constructs were available, one would expect the knock-down of SHP-2 in CD31 
positive Jurkats to impair the detachment of Jurkats from THP-1.  As postulated the 
knock-down of SHP-2 expression would prevent SHP-2 acting as a docking protein 
for the recruitment of downstream signalling and adapter molecules to CD31.   
As this work has been with cell lines, it would be interesting to confirm the findings 
in vivo.  A model of macrophage-leukocyte interactions has previously been used in 
the laboratory, where mouse thymocytes are introduced into the greater omental 






previously shown with this model, more thymocytes from CD31 wild-type mice 
were recovered than from knock-out mice, when injected as a mixed population into 
wild type mice (Dr Simon Watson, personal communication, University of 
Edinburgh, UK), confirming previous results with the in vitro flow chamber model 
84, and with work presented here, that CD31 is required for viable leukocytes to 
detach.  This model could be adapted to introduce reconstituted knock-out leukocytes 
with either mutations in CD31 itself, or knock-down potential targets such as SHP-2 
from CD31 positive leukocytes.  
In summary, for viable leukocytes to actively detach from macrophages when bound 
via CD31, the leukocyte appears to require the ITIM of CD31 intact.  This is most 
probably in order to recruit the signalling and adapter molecule SHP-2, which may 

















3.1.1 SHP-1 and SHP-2  
In addition to mediating homophilic interactions between cells, it has become 
apparent that CD31 also participates in intracellular signalling.  In platelets, full-
length CD31 participates in cell signalling by binding SHP-2, an SH2 domain 
containing phosphatase.  Upon further investigation, CD31 phosphopeptides 
encompassing residues 658-668 and 681-691 were found to bind SHP-2 130. 
Several signalling proteins have previously been shown to bind to the cytoplasmic 
domain of CD31. A study using BIAcore analysis showed the SH2 domains of SHP-
1, SHP-2, SHIP and PLC-γ bind CD31.  SHP-2 binds CD31 preferentially via Y663, 
whereas SHIP binds via Y686.  Binding of SHP-1 and PLC-γ to CD31 required both 
tyrosines 63.  
The binding of SHP-1 and SHP-2 phosphatases is required for CD31-mediated B cell 
receptor regulation. When lysates from DT40 chicken B cells were incubated with 
phosphopeptides of the cytoplasmic domain of CD31, only tyrosine phosphorylated 
phosphopeptides bound SHP-1 and SHP-2; and binding was shown to be dependent 
on both ITIM tyrosines 62.  
 
3.1.2 Rho GTPases 
Rho family GTPases are involved in cell motility by modulating the actin 
cytoskeleton.  Rac can also activate Rho, and it is likely that Rho GTPases regulate 
motility by acting as molecular switches. In fibroblasts Rho supports the production 







be involved in regulating stress fibres and focal adhesions, and may regulate Rho 
through RasGAPp120 association with RhoGAPp190 146.  A mechanism for the 
regulation of migration of endothelial cells was recently described 61 where CD31 
influenced signalling through Rho, as CD31KO endothelial cells were found to have 
a defect in RhoGTP loading.  Knocking down CD31 with siRNA in HUVEC also 
resulted in a decrease in levels of RhoGTP.   
In endothelial cells, tyrosine phosphorylated β-catenin binds to CD31.  In EOMA 
(haemangioendothelioma) cells, both CD31 and β-catenin was found to be tyrosine 
phosphorylated, allowing a complex with SHP-2 to be formed.  This observation 
suggests that β-catenin dephosphorylation mediated by SHP-2 occurs on the CD31 
scaffold.  CD31 may modulate the phosphorylation and function of β-catenin as a 
reservoir of tyrosine phosphorylated β-catenin 65.   
 
3.1.3 Viable and Apoptotic Signalling 
In a flow-chamber system, both viable and apoptotic neutrophils adhered to 
macrophages at 20˚C, a temperature where cytoskeletal reorganisation was inhibited.  
When the temperature was raised to 37˚C, the viable cells actively detached from the 
macrophages, whereas the apoptotic cells remained attached.  CD31 expressed on the 
surface of neutrophils was shown to mediate the interaction between the leukocyte 
and the macrophage. Viable Jurkat T cells stably transfected with a CD31 construct 
missing the ITIM tyrosines were also unable to detach, showing that fully-functional 
CD31 was required to transmit detachment signals, allowing the leukocyte to escape.  







through the action of SHP-1 and SHP-2 phosphatases.  SHP-1 did not constitutively 
associate with CD31, and SHP-2 was cleaved and did not bind the cytoplasmic 
domain upon pervanadate treatment 84.  The differential signalling in viable and 
apoptotic cells may account for the ability of the viable cell to escape engulfment. 
During apoptosis of endothelial cells, CD31 was reported to be cleaved and then 
shed into the supernatant as a soluble extracellular fragment of 100kDa, leaving a 
truncated fragment of 28kDa comprising of a small portion of the extracellular 
domain, the transmembrane region and the cytoplasmic domain in the cell 
membrane. This truncated form was found to differentially associate with the 
cytoplasmic signalling molecule γ-catenin, but not with β-catenin, inhibit cell 
growth, and even promote apoptotic cell death when expressed in human colon 
carcinoma cells 92.  CD31 may therefore be recruiting different proteins in a viable 
cell compared with an apoptotic cell, and this provides an explanation as to why a 
viable cell is able to detach and an apoptotic cell is not able, and is therefore 
internalised.   
 
3.1.4 Experimental Approach 
To identify the proteins bound to the cytoplasmic domain of CD31, GST-CD31 
fusion proteins were generated and used in GST pulldowns of viable CD31 negative 
Jurkat lysates. It was thought most appropriate to investigate the proteins that bind to 
CD31 in the viable cell initially, and then determine whether these interactions still 







GST binds to glutathione with high affinity allowing the fusion proteins to be rapidly 
and specifically isolated together with potential binding candidates present in cell 
lysates; this is a common system that has been previously used in cell signalling 
studies of protein interactions 147.  Other high affinity interactions that could have 
been used included biotin-streptavidin and His-nickel.  However, since the initial 
vectors containing the CD31 cytoplasmic domain used previously in the laboratory 
and by others (gift from Dr Michael Douglas, Birmingham University, UK) included 
an N-terminal GST tag, it was decided to make all constructs in this manner.  
Attempts were initially made to produce a cytoplasmic domain construct with an N-
terminal biotin tag, but this was unsuccessful. 
 
3.2 Results 
Lysates from CD31 negative Jurkats were used in subsequent analysis unless stated 
otherwise to avoid substrate competition with endogenous CD31.  All CD31 
cytoplasmic domain constructs were produced (see Appendix for details of 
construction, induction and purification) with an N-terminal GST tag.  The 
recombinant proteins were full length CD31 cytoplasmic domain, and point 
mutations at ITIM tyrosines Y663, Y686, Y663/686, and tyrosine 701 to 
phenylalanine and serine 620, 669, 673 and 702 to alanine mutant (QSA) (Figure 

















Figure 3.2:1.  Diagrammatic representation of recombinant proteins generated, 
































GST-fusion protein pulldown analysis revealed that SHP-2 binds to the cytoplasmic 
domain of CD31, in an ITIM dependent manner, as the Y663F/Y686F construct did 
not bind SHP-2 (Figure 3.2:2).  There was reduced binding of SHP-2 with Y663F 
and Y686F constructs, supporting previous work  62.  The blot was reprobed for GST 
to confirm equal protein loading.   
SHP-1 binds to the cytoplasmic domain of CD31 at a lower level than SHP-2, and is 
dependent on intact ITIM tyrosines, which recapitulates previous work57 (Figure 
3.2:3).  Equivalent protein loading was confirmed by reprobing for GST.  The 
pulldowns were also probed for p120 RasGAP (Figure 3.2:4), and this was found not 
to bind to the cytoplasmic domain of CD31, equal loading was confirmed by 
reprobing with anti-GST antibodies.   
Given the previous findings of β-catenin binding to CD31 in endothelial cells, and in 
complex with SHP-2 65, GST pulldowns with either wild type and tyrosine mutant 
CD31 constructs show β-catenin did not bind to the cytoplasmic domain of CD31 
(Figure 3.2:5), the blot was reprobed with GST to confirm equal protein loading. 
Src family kinases have been shown to phosphorylate CD31, but src was not 
detectable in a GST-CD31 pulldown (Figure 3.2:6).  Src may not be binding to CD31 
directly, but may bind to other proteins the plasma membrane and phosphorylate 















Figure 3.2:2.  CD31 negative Jurkat lysates were incubated with GST-CD31 point 
mutant constructs in a GST pulldown assay, separated by 10% SDS-PAGE and 
Western blotted for SHP-2 (top) and GST to confirm equivalent protein loading (lower).  
SHP-2 binds to wild-type, QSA and Y701F CD31, with less binding to Y663F, Y686F 









Figure 3.2:3.  GST pulldown (as described previously [Figure 3.2:2]) of Jurkat lysates 
show SHP-1 binding to CD31 is dependent on intact ITIM tyrosines and is unaffected 
































































Figure 3.2:4.  GST pulldown (as described previously [Figure 3.2:2]) of Jurkat lysates 
show p120 RasGAP does not bind to CD31 cytoplasmic domain (top) reprobed with 









Figure 3.2:5.  GST pulldown (as described previously [Figure 3.2:2]) show β-catenin 
does not bind to the cytoplasmic domain of CD31 (top), reprobed for GST (lower) to 



























































Figure 3.2:6.  GST pulldown (as described previously [Figure 3.2:2]) show src does 
not bind to the cytoplasmic domain of CD31 (top), reprobed for GST (lower) to confirm 


























It has been suggested that talin may be involved in CD31 mediated activation of 
integrins (Personal communication, Dr David Critchley, Leicester University, UK).  
To explore this we investigated whether there was a direct link between CD31 and 
talin, using a construct of the talin FERM domain with an N-terminal His tag in 
pulldown assays.   
The His-talin construct was transformed into BL21 E. coli and purified with 
magnetic nickel-coated beads (see Appendix).  Pulldowns using the original buffer 
condition as described 76 with either His-talin or GST-CD31, and probing for CD31 
and talin respectively found no association between talin FERM domain and CD31 
cytoplasmic domain. Changing the buffer conditions to those used in the optimised 
GST pulldowns, and probing for talin binding to CD31 did not detect any direct 













Figure 3.2:7.  GST pulldown (as described previously [Figure 3.2:2]) with ITIM mutant, 
































GST  WT Y663F Y686F Y663F/Y686F Y701F QSA
SHP-1         
SHP-2         
RasGAP p120        
RhoGAP p190        
β-catenin        
c-src        
Talin         
Table 3.2:1.  Summary table showing association between different GST-CD31 








3.2.1 Apoptotic vs Viable GST Pulldowns 
It has proven difficult to induce Jurkat cells to undergo apoptosis with minimal 
necrosis.  Using a range of concentrations of Fas ligand (CH11) antibody together 
with various chemical treatments, the cells were found to be very resistant to 
apoptosis and progressed instead to necrotic cell death.  Treatment of Jurkats with 
10mM cycloheximide and 50µM etoposide induced massive necrosis (Figure 3.2:8).  
Inducing apoptosis with different concentrations of CH11 also produced high levels 
of necrosis (Figure 3.2:9).  We therefore decided to use neutrophils as they undergo 
apoptosis readily following culture overnight in vitro with low levels of necrosis.   
Apoptosis and necrosis was measured by annexin V/ propidium iodide (PI) staining 
and flow cytometric analysis (FACSCalibur, BD Biosciences).  The outer membrane 
of the cell contains, amongst proteins, zwitterionic phospholipids, whereas the inner 
membrane has the aminophospholipids phosphatidylethanolamine (PE) and 
phosphatidylserine (PS).  The aminophospholipid translocase catalyses the 
movement of aminophospholipids from the outer to the inner membrane.  When the 
cell undergoes apoptosis, this translocase is inactivated, and PS becomes exposed on 
the cell surface 110. 
Exposure of PS is detectable using annexin V, which can be conjugated to FITC, 
amongst other fluorochromes, and is detectable through the FL-1 channel.  Cell 
membrane integrity is lost during the late stages of apoptosis and PI can enter the cell 
and bind DNA, this is detectable through the FL-2 channel.  Viable cells have low 
annexin V/PI staining, whereas apoptotic populations have high annexin V and low 







3.2.2 Neutrophil Pulldowns 
Freshly isolated neutrophils were mostly viable (97.6% unstained, 0.28% annexin V 
positive, 0.73% propidium iodide positive and 1.43% both annexin V/propidium 
iodide).  Aged neutrophils have 46.4% unstained, 44.4% annexin V positive, 5.03% 
propidium iodide positive and 7.19% annexin V/propidium iodide positive (Figure 
3.2:10).   
GST pulldowns were performed as described (Materials and Methods) with the 
following modifications; the lysates were not precleared with glutathione beads 
overnight as proteolysis occurred over this time frame.  (Extra protease and 
phosphatase inhibitors were added in addition to those described in Material and 
Methods, 1 protease inhibitor cocktail tablet [Roche], 10mM β-glycerophosphate, 
2mM levamisole, 10mM NaF, 10mM Na3VO4) with either freshly isolated or aged 
neutrophils (10 X106 cells/ml lysate). 
As previously shown in viable Jurkats, SHP-1 binds to the cytoplasmic domain of 
CD31, in viable and aged neutrophils, SHP-1 binds to the cytoplasmic domain of 
CD31 (Figure 3.2:11).  SHP-2 has also been shown to bind to CD31 in viable 
Jurkats, but is degraded in apoptotic Jurkats 84.  SHP-2 was present in both viable and 
aged neutrophils, and bound to CD31 in both conditions (Figure 3.2:12). 
Interestingly, we found that phosphotyrosine levels of CD31 were decreased 
following incubation with aged neutrophil lysates, which may suggest that aged 




























Figure 3.2:8.  Treatment of CD31 negative Jurkats with CH11 and 10mM cycloheximide 

























Figure 3.2:9.  CH11 treatment of CD31 negative Jurkats at concentrations from 50 to 















Figure 3.2:10.  Freshly isolated and aged neutrophils stained with annexin V and 
propidium iodide show freshly isolated neutrophils have 97.6% unstained, 0.28% 
annexin V positive, 0.73% propidium iodide positive and 1.43% both annexin 
V/propidium iodide.  Aged neutrophils have 46.6% unstained, 44.4% annexin V 
positive, 5.03% propidium iodide positive and 7.19% annexin V/propidium iodide 









Figure 3.2:11.  Freshly isolated and aged overnight neutrophil pulldown probed for 
SHP-1, shows binding of SHP-1 to CD31 in viable and aged neutrophils (top), reprobed 
for GST (lower) to confirm equal protein loading. 
 














































































Figure 3.2:12.  Freshly isolated and aged overnight neutrophil pulldown probed for 
SHP-2 shows CD31 binds SHP-2 in viable and aged neutrophils (top), reprobed for 

















































Figure 3.2:13.  Freshly isolated and aged overnight neutrophil pulldown probed for 
phosphotyrosine (top) showing decreased tyrosine phosphorylation of CD31 in aged 










































3.2.3 MALDI-TOF Protein Finger Printing 
As well as investigating GST pulldowns by Western blot for suspected binding 
partners, we also included an unbiased approach to identify novel candidates binding 
to the cytoplasmic domain of CD31.  MALDI-TOF (matrix assisted laser desorption 
time of flight spectroscopy) protein fingerprinting provides an accurate method to 
identify unknown protein bands on a gel.  Briefly, proteins are separated on SDS-
PAGE and excised from the gel.  The protein is then removed from the gel by 
washing with acetonitrile, and is then digested with trypsin.  The protein fragments 
are then mixed with a matrix which is ionised by a laser.  The fragments and matrix 
then fly down to a detector, and their time of flight is measured.  Larger fragments 
take longer to reach the detector than smaller fragments.  The detector then produces 
the results as peaks of protein mass, which can then be compared with a database of 
known proteins to allow identification of CD31 binding partners. 
The GST pulldown was performed with GST alone to act as a negative control, wild-
type, Y663F, Y686F, Y663F/Y686F, Y701F and QSA mutant constructs as 
described (Materials and Methods) and the proteins separated on an 8-16% Tris-
glycine SDS PAGE.  The bands were visualised by silver staining (Figure 3.2:14). 
Bands present in the GST alone pulldown were discounted as non-specific, and their 
presence in the other pulldowns was ignored.  Between the different pulldowns it 
was noted that there were slight differences in the molecular weights of the proteins, 
particularly at the lower molecular weights.  However, large differences were 







The proteins binding to wild type cytoplasmic domain were of immediate interest, 
and this pulldown sample was sent for MALDI-TOF analysis (Fingerprints 
Proteomics Services, Dundee, UK).  Utilising known binding partners from the 
literature or from work in this laboratory, the arrowed bands were selected as being 
potentially novel proteins (Figure 3.2:15).  To compare between phosphorylated, 
(wild-type CD31) and unphosphorylated (Y663F/Y686F mutant) CD31, and 
determine whether there were different proteins associating due to phosphorylation 
of the cytoplasmic domain, pulldowns were performed and separated on SDS-PAGE 
(Figure 3.2:16).  Bands unique to the CD31 lanes were excised for MALDI-TOF 
analysis.  Table 3.2:17 shows the proteins identified from Swiss-prot database where 
the percentage confidence interval (% C.I.) was greater than 95%.  14-3-3ε is an 
adapter protein that acts as a ‘molecular anvil’ to bring two proteins together, and 
thereby facilitating an interaction.  Proteins binding to 14-3-3ε must be 
phosphorylated 148, and since CD31 can be phosphorylated, and may be utilising 14-
3-3ε to mediate interactions with other signalling molecules during migration. 
During the formation of focal adhesions, structures termed spreading initiation 
centres (SIC) form at the point of contact in the cytoplasm.  These structures contain 
focal adhesion markers, actin and RNA and RNA binding proteins 149.  CD31 may 
form these structures during the process of forming focal adhesion complexes, and 
this may be why the RNA helicase EIF3 was identified as binding to the cytoplasmic 







The other identified proteins, cyclophilin A, profilin, L-plastin, α-enolase and myosin 
have been shown to be glutathionated in T cells that are oxidatively stressed 150.  
Using the GST-glutathione affinity system may have selectively pulled out these 
























Figure 3.2:14.  Silver stained 8-16% SDS-PAGE showing proteins of different 


















































Figure 3.2:15.  Coomassie stained 12-18% MOPS gel of GST pulldown from negative 
Jurkat lysates. The four lanes contain 5μl, 10 μl, 15 μl and 20 μl of the sample to gauge 
for overloading. The arrows show bands that were extracted for MALDI-TOF MS/MS 
analysis. 
 

































Figure 3.2:16.  Coomassie stained 12-18% MOPS gel of GST-CD31 pulldowns from 
negative Jurkat lysates, with GST alone, wild type and Y663/Y686F CD31 as bait.  The 



























Table 3.2:17.  Table of results from MALDI-TOF analysis showing proteins identified, 
































To investigate the proteins that were binding to the cytoplasmic domain of CD31, 
GST pulldown with N-terminal tagged CD31 constructs was used.  However, this 
method required a lot of optimisation, as initial attempts with the affinity isolation 
yielded non-specific binding of SHP-2 and Hsp90 to the GST tag.  Increasing 
concentrations of NaCl did not remove the non-specificity of molecular interactions, 
neither did the addition of a chaotrope (NaI) to destabilise hydrophobic interactions.  
Preclearing the lysates before pulldown with either beads or GST was also 
unsuccessful at removing the non-specific binding.  
Performing a literature search found three published methods of pulldown that used 
different compositions of lysis buffer and washing conditions that were subsequently 
tested for minimal non-specific binding to the GST tag.  The lysis buffer must 
contain both a detergent and NaCl, and the cell lysate must be precleared with 
glutathione-agarose beads overnight prior to performing the GST pulldown.   
The GST-CD31 cytoplasmic domain constructs must also be phosphorylated in vitro, 
as they were not phosphorylated by being produced in the bacteria or by incubating 
with the cell lysate.  Phosphorylation of the cytoplasmic domain was essential to 
bind the SH2 domain containing phosphatases and other signalling molecules 
dependent on tyrosine phosphorylation.  There was no association of c-src with the 
cytoplasmic domain of CD31 from GST pulldown analysis, and this observation is 
consistent with  previous work where although c-src is able to phosphorylate CD31, 







The tyrosine phosphorylated cytoplasmic domain of CD31 has been shown to 
associate with several signalling molecules in the cytoplasm.  The SH2 domain 
containing phosphatases SHP-1 and SHP-2 bind to specific tyrosine residues 
identified as part of an ITIM (immunoreceptor tyrosine-based inhibitory motif).  
SHP-1 requires an intact ITIM for binding to CD31, whereas SHP-2 requires Y663.  
Phospholipase C-γ (PLC- γ) is also reported to bind to CD31 and requires an intact 
ITIM 63.   
A complex of β-catenin and SHP-2 on the CD31 scaffold has been hypothesised to 
allow dephosphorylation of β-catenin and the recycling of β-catenin to the 
endothelial cell junction 65.    β-catenin binds the cytoplasmic domains of cell 
adhesion molecules such as VE cadherin and links VE cadherin to the actin 
cytoskeleton 151.  β-catenin did not bind to the cytoplasmic domain constructs in 
leukocytes which may suggest that it is not phosphorylated, or that it may function in 
a different manner in leukocytes compared with endothelial cells. 
 
The association of signalling proteins with the cytoplasmic domain of CD31 in 
viable cells could explain why viable cells are able to actively detach from 
macrophages.  However, in the apoptotic cell, this signalling pathway could be 
perturbed, with differential recruitment of signalling and adapter molecules resulting 
in the cell being unable to engage its motor machinery and escape engulfment.  
 
Investigation with point mutant GST-CD31 cytoplasmic domain constructs showed 







requires either tyrosine residue which confirms previous findings 63.  These 
phosphatases may be acting as docking proteins themselves for downstream 
signalling molecules in addition to their established function of dephosphorylating 
CD31.  SHP-2 has been shown to bind to Gab1 and Grb2 via their SH-2 domains.  
Gab1 (Grb-associated binder-1) recruits a variety of signalling proteins including Crk 
and PLC-γ in the context of receptor-mediated signalling 152.  Crk binds to pleckstrin 
homology domains of various signalling proteins via its SH-3 domains including 
DOCK180; which is a guanidine exchange factor of Rac, and is involved in 
lamellipodia formation and cell motility 153. 
Grb2 also recruits SOS (son of sevenless), which is an exchange factor of Ras, and 
this signalling pathway may lead to the activation of Ras 154, and the regulation of 
focal adhesion contacts 146. 
 
In lysates of viable and aged neutrophils, SHP-1 and SHP-2 were found to be 
associated with the cytoplasmic domain of CD31, and there were decreased 
phosphotyrosine levels of CD31 in aged lysates.  This result does not wholly confirm 
previous work with Jurkats 84 where SHP-2 was found to be degraded, and there was 
reduced SHP-1 association to CD31 in apoptotic leukocytes.  However, there was 
reduced phosphotyrosine in both systems.  In endothelial cells CD31 homophilic 
interactions suppresses cell death and dephosphorylating CD31 causes detachment 
and anoiksis 155.  Dephosphorylation of CD31 may be a consequence of apoptosis 
and altered signalling within the cell which may lead to firm attachment to 







The modulation of the actin cytoskeleton by the regulation of Rho family members is 
required for cell motility 61.  The guanidine exchange factor RasGAP5 (p120) was 
not detected as binding to the cytoplasmic domain of CD31.  However, the exchange 
factor may be acting indirectly with CD31 further downstream to regulate migration.  
Previous work has shown that CD31KO endothelial cells have a defect in RhoGTP 
loading, and RhoGTP is required for migration of CD31 positive endothelial cells 61, 
so it is likely that exchange factors for Rho family members are involved in CD31-
mediated signalling.  
 
The possible association of the integrin binding protein talin with CD31 was also 
explored, but these studies did not demonstrate binding of talin to the cytoplasmic 
domain constructs in Jurkats.  As CD31 activates integrins, it could be binding talin 
to achieve this indirectly, but from the work presented here, this possibility is 
unlikely. 
 
As well looking at suspected candidates binding to CD31 via Western blotting, an 
unbiased approach of pulldown then MALDI-TOF was taken to identify novel 
candidates.  Although many proteins can be identified as binding to the cytoplasmic 
domain, the issue of specificity was raised.  Washing the pulldowns with high 
stringency buffers can disrupt weaker interactions; conversely washing with a buffer 
of too low stringency can result in non-specific proteins binding.  Running GST 







specific interactions binding to the GST tag, or in the case of the mutant confirm the 
requirement of certain residues in the cytoplasmic domain for protein binding.   
 
MALDI-TOF identified 14-3-3ε as binding to the wild-type cytoplasmic domain of 
CD31.  This is an adapter protein that binds phosphorylated proteins, and SH-2-
domain containing proteins 148.  14-3-3ε could be mediating interactions between 
SHP-2 and other signalling molecules such as Grb2, facilitating the role of CD31 as a 
scaffolding molecule. 
From the Y663F/Y686F mutant analysis, one interesting protein identified was eIF3 
(elongation initiation factor 3).  This is an RNA helicase, responsible for unwinding 
RNA prior to translation.  Spreading initiation centres were recently discovered as 
initial points of adhesion during cell spreading and contain focal adhesion proteins, 
actin, RNA binding proteins and RNA 149.  CD31 may be participating in the 
formation of these structures prior to focal adhesions and firmer attachment.   
Of the other proteins identified, cyclophilin A, profilin, L-plastin, α-enolase and 
myosin, all have been found to be glutathionated in T lymphocytes 150.  This suggests 
that these proteins represent non-specific contaminants that are binding to the GST 
and not to CD31.  Using an alternative system for tagging the CD31 constructs such 
as His-nickel or biotin-streptavidin may eliminate this possibility.  However, it is 
also possible that these protein interactions with CD31 may be real, and could further 
link CD31 to the actin cytoskeletal regulatory machinery which may therefore 








As SHP-2 was detected as binding to the cytoplasmic domain of CD31 and can also 
function as a docking protein, probing leukocyte lysates with a recombinant SHP-2 
and SHP-2 with a point mutation in its catalytic site may elucidate the signalling 
pathway of CD31-mediated migration.  A Western blotting and MALDI-TOF 
approach could also be used here.  Once candidates have been identified, they could 
be subject to siRNA to knock-down expression in the functional attachment assay to 














4.1.1 Project Background 
The potential interaction of Hsp90 with CD31 was discovered by others in this 
laboratory using a number of different, but complementary approaches, including 
genetic screens, CD31 cross linking and immunoprecipitation studies.   To ascertain 
if Hsp90 binding to CD31 was a specific interaction, and to elucidate which residues 
in the cytoplasmic domain were important for mediating binding, investigation with 
GST pulldowns was performed.  
 
4.1.2 Chaperone Functions of Hsp90  
Hsp90 is an abundant (1% soluble cellular protein) cytoplasmic chaperone that is 
involved in ensuring correct folding and maturation of many proteins.  An important 
regulatory function of Hsp90 is the binding of steroid hormone receptors that are free 
from hormone ligand.  Binding of hormone causes dissociation of the Hsp90-
receptor complex and dimerisation of the receptor, thereby allowing it to bind 
specific DNA glucocorticoid response elements and regulate transcription 156.  
 
Hsp90 functions in co-operation with other co-chaperones Hsp70, Hop (hsp-
organising protein), Hsp40 and p23 157.  For efficient binding of hormone to the 
receptor, the chaperone complex must bind to the receptor prior to its engagement 
with steroid 158.  The steroid hormone receptor client protein binds Hsp70 and Hsp40 
to form a complex capable of binding Hsp90.  An ATP-dependent reaction then 






and hold Hsp90 in this active state.  The client protein and chaperone complex then 
associates with the immunophilins, peptidyl-prolyl isomerases, containing TPR 
(tetratricopeptide repeats) motifs, such as FKBP52159.  The immunophilins bind to 
dynein, a motor protein that moves the client protein in the direction of the nucleus.  
Once inside the nucleus, the chaperone complex dissociates from the client protein, 
allowing the receptor-hormone complex to bind to chromatin and exert its effects 
upon the cell 160.  A schematic of the formation of the chaperone complex with 



















Figure 4.1:1.  Schematic of Hsp90 function in steroid hormone receptor activation.  
Hsp90 forms a complex with Hsp70, Hsp40 and Hop.  The chaperone complex binds to 
the inactive receptor, and in an ATP-dependent reaction cause the receptor to open 
and bind hormone.  p23 binds to stabilise the reaction, then Hop and Hsp70 are 
released.  The immunophilins (IMM) can then bind to Hsp90 via TPR motifs.  The 
whole chaperone complex can then translocate to the nucleus where the receptor can 






Calmodulin is involved in intracellular calcium signalling, and has been shown to 
bind to Hsp90 in complex with the glucocorticoid receptor 162.  Interestingly, 
calmodulin has been shown to associate with CD31 in platelets, an interaction that 
was dependent on the specific sequence 599RKAKAK604 and the association is 
increased with the addition of Ca2+.  This interaction is thought to regulate the 
cleavage of the cytoplasmic domain of CD31 163.   
 
4.1.3 Src Family Kinases 
Src family kinases are also substrates of Hsp90 with v-src from Rous sarcoma virus 
being the first to be identified.  Immediately after v-src synthesis, Hsp90 was also co-
precipitated.  Binding of Hsp90 renders the kinase incapable of autophosphorylation, 
and reduces the capacity of v-src to phosphorylate its substrates.  However, when the 
kinase is inserted into the membrane its kinase activity becomes maximal.  Thus, 
Hsp90 prevents the inappropriate activation of v-src prior to reaching the membrane.  
Contrastingly, the cellular homolog c-src, interacts very weakly with Hsp90 upon its 
transit to the membrane 164.  Lck, another src family kinase member, requires Hsp90 
during synthesis and transport to the membrane but the mature form does not require 
Hsp90 165. 
 
4.1.4 Tetratrico Peptide Repeats 
Hsp90 interacts with co-chaperones that contain tetratrico peptide repeats (TPRs).  
The TPR fold is found in many organisms and mediates interactions between 






processes including cell cycle control, transcription, protein transport, folding and 
turnover.  The TPR is a 34 amino acid motif containing amino acids with basic 
charges and the following consensus residues –W-LG-Y-A-F-A-P.  TPR motifs form 
amphipathic helices, containing both hydrophilic and hydrophobic residues, 
comprising of approximately  50% α-helices, where the helices form domains A and 
B 166.  Domain A spans residues W, LG and Y, and domain B residues A, F, A and P.  
The TPR motifs are arranged in an antiparallel fashion at angles of 24˚ to form a 
right-handed ‘staircase’, creating an amphipathic channel with which proteins 
interact 167-170.   
The TPR is important in mediating the interactions between Hop, Hsp70 and Hsp90.  
Hop contains three three-TPR motifs, the N-terminal TPR binds Hsp70, the middle 
repeat binds Hsp90, the binding partner for the third TPR motif has yet to be 
discovered  171. 
 
4.2 Results 
4.2.1 ITIM Point Mutations of CD31  
GST pulldowns with wild-type, tyrosine 663 (Y663F), 686 (Y686F) and both 663 
and 686 (Y663F/Y686F), 701 (Y701F) and serine (QSA) point mutant CD31 
demonstrated that Hsp90 was capable of interacting with the cytoplasmic domain of 
CD31, and that this interaction was independent of the ITIM, Y701 or serine 
mutation, and hence independent of phosphorylation of the cytoplasmic domain of 







4.2.2 Truncation of CD31  
To determine the residues of CD31 critical for Hsp90 binding, a series of truncated 
constructs were generated (Figure 4.2:2).  The constructs are numbered from the first 
residue after the transmembrane region and the truncated regions are denoted with 
the prefix Δ.  To begin with, the constructs CD31TM30Δ88 (i.e. is the first 30 amino 
acids with a truncation of the last 88), CD31TMΔ25,93, CD31TMΔ50,68 and 
CD31TM104,Δ14 were generated. When these constructs were used in GST 
pulldowns the only construct for which binding to Hsp90 could not be demonstrated 
was CD31TMΔ50,68 (Figure 4.2:3). 
The CD31TMΔ50,68 construct became a focus for further C-terminal truncation, as 
the results thus far suggested there were critical amino acids present in the distal 
region of the cytoplasmic domain required for Hsp90 binding.  Further truncations of 
this region were generated CD31TM31,Δ87, CD31TM37,Δ81 and CD31TM41Δ77.  
In the course of the production of these proteins, the GST pulldown method was 
optimised for other proteins to remove non-specific binding to the GST alone.  With 
optimisation achieved, the pulldowns with all truncated constructs including the new 
ones were performed (Figure 4.2:4).  Both CD31TM30,Δ88  and CD31TM19,Δ109  
were found to bind Hsp90, perhaps because both of these constructs contain the 
calmodulin binding region (KCYFLRKAK) 163. 
CD31TMΔ25,93 , CD31TMΔ50,68, and CD31TM104,Δ14 also bind Hsp90.  Hsp90 
association with CD31TM30,Δ88 and CD31TM104,Δ14 was similar to that observed 






CD31TMΔ50,68 construct.  The further truncations CD31TM37,Δ81 and 
CD31TM41Δ77 did not bind Hsp90, suggesting there are residues required for 
binding to the cytoplasmic domain present in the missing regions (residues 
MEANSHYGHNDDVG).  The blot was reprobed for SHP-2 binding, as SHP-2 
associates with phosphorylated CD31, this provides a positive control for correct 
folding, as expected only constructs with an intact ITIM were able to bind SHP-2 
(wild-type CD31, CD31TMΔ25,93, CD31TM31,Δ87, CD31TMΔ50,68, and 
CD31TM104,Δ14).  A summary of the ability of each construct to bind both Hsp90 












Figure 4.2:1.  GST pulldown performed with tyrosine and serine mutants showing 













Figure 4.2:2.  Schematic showing truncated CD31 constructs.  The residues 
highlighted show the beginning or ending of the amino acid sequence at the position 






























Bam HI Sal I
CD31TM19,Δ109 …EMSRPAVP
GST
Bam HI Sal I
…LNNSNNEK CD31TM30,Δ88  
GST
















Bam HI Not I
…SSAESPDA CD31TM104,Δ14  
GST















Figure 4.2:3.  GST pulldowns with CD31 wild-type, CD31TM30,Δ88, CD31TMΔ25,93, 
CD31TMΔ50,68, and CD31TM104,Δ14, shows CD31TMΔ50,68 to be the only construct 









Figure 4.2:4.  Optimisation of the GST pulldown method and truncation of the 
cytoplasmic domain of CD31 reveals multiple binding sites for Hsp90.  Reprobing the 
membrane for SHP-2 shows the constructs to be correctly folded, with those 
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Figure 4.2:5.  Summary of truncated GST-CD31 constructs with amino acid sequence 
and ability to bind Hsp90 and SHP-2 from CD31 negative Jurkat lysates. 
GST




Bam HI Sal I
CD31TM19,Δ109 …EMSRPAVP
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Bam HI Not I
…SSAESPDA CD31TM104,Δ14  
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4.2.3 Sequencing Alignment 
A ribbon diagram of a TPR-containing protein demonstrates the A and B helix 
regions and shows the residues important for Hsp90 binding (Figure 4.2:6).  A 3-
dimensional model shows the amphipathic helix and carboxylic clamp that TPR-
containing proteins use to bind Hsp90 (Figure 4.2:7).  Sequence alignment with other 
TPR-containing proteins that bind Hsp90, such as FKB51 and Hop, which is part of 
the chaperone complex with Hsp90 and Hsp70, shows CD31 may have some 
sequence homology.  The most conserved regions are highlighted, and the position of 
the putative helix regions is shown.  Aligning the truncated constructs shows that a 
conserved region containing the sequence SNNEK is missing from the construct 














Figure 4.2:6. Ribbon drawing of an Hsp90 binding protein showing the helix regions A 
and B and the Hsp90 binding cleft amino acids denoted by single letter code 








Figure 4.2:7.  3-dimensional model of an Hsp90 binding protein showing the 
amphipathic helix formed around Hsp90 (ball and stick model) (Personal 























Figure 4.2:8. Clustal X CD31 cytoplasmic domain amino acid sequence aligned with 
known Hsp90 binding proteins containing TPR motifs.  The boxes marked helix A and 
B denote putative helix regions.  The pink boxes show the most conserved regions 
between the Hsp90 binding proteins and CD31. Amino acid sequence examination of 










HELIX BHELIX AHELIX B




FKB51   LLAAFLNLAMCYLKLREYTKAVECCDKALG-------LDSAN EKGLYRRGEAQLLMNEFESAKGDFEKVLEVNPQN 
FKB52   -LASHLNLAMCHLKLQAFSAAIESCNKALE-------LDSNN EKGLFRRGEAHLAVNDFELARADFQKVLQLYPNN 
CyP40   --SCVLNIGACKLKMSNWQGAIDSCLEALE-------LDPSN TKALYRRAQGWQGLKEYDQALADLKKAQGIAPED 
HOPa    -HVLYSNRSAAYAKKGDYQKAYEDGCKTVD-------LKPDW GKGYSRKAAALEFLNRFEEAKRTYEEGLKHEANN 
HOPb    --KLYSNRAACYTKLLEFQLALKDCEECIQ-------LEPTF IKGYTRKAAALEAMKDYTKAMDVYQKALDLDSSC 
PP5     -AIYYGNRSLAYLRTECYGYALGDATRAIE-------LDKKY IKGYYRRAASNMALGKFRAALRDYETVVKVKPHD 
              * . .  :   :  *     . :        *.     *.  *:. .   :  :  *    :..  . . . 













4.2.4 Site-Directed Mutagenesis of CD31  
Comparing the sequence of CD31 with TPR-containing proteins show conserved 
regions SNNEK and downstream lysines.  Site-directed mutagenesis was employed 
to specifically target these particular residues.  Site directed mutagenesis requires the 
target sequence to be in a plasmid from E. coli which is methylated.  Primers 
containing the mutation required are annealed to the plasmid and PCR amplification 
of the whole plasmid occurs, generating a nicked plasmid with the mutation in the 
target sequence.  The original plasmid template that does not have any mutations is 
methylated, is therefore sensitive to Dpn I digestion, whereas the synthetic mutant 
plasmid is not.  The pure synthetic mutant plasmid can then be transformed into 
competent cells that repair the nicks. 
 
Mutations of the conserved residues were generated, N27 to A, N27 to D, (E28 to 
A/K29 to A/M30 to A), K54 to A, (K85 to A/K86 to A) (Figure 4.2:9).  (For details 
of construction, and purification see Appendix). 
Pulldowns with these constructs revealed the mutation CD31N27A from asparagine 
to alanine did not bind Hsp90, but changing this residue to aspartic acid did not 
prevent the binding of Hsp90.  Mutating three amino acids including the basic lysine 
residue K29 (CD31E28A/K29A/M30A in the putative TPR motif) did not have any 
effect on Hsp90 binding, suggesting that single mutation of the cytoplasmic domain 
of CD31 may not impact upon the binding surface required by Hsp90. 
The single lysine mutation CD31 K54A did not prevent Hsp90 binding, suggesting 






of the lysines 85 and 86 reduced Hsp90 binding to the cytoplasmic domain of CD31.  
These lysines are postulated to be part of the carboxylic clamp region that may grasp 
Hsp90 in another region downstream of the TPR motif.  All mutagenesis constructs 
were capable of binding SHP-2, which demonstrates the proteins are correctly 
folded.  Blots were also reprobed for GST to confirm equivalent protein loading 


















Figure 4.2:9.  Schematic of site directed mutagenesis constructs showing the SNNEK 
region and lysine mutants. 
GST
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Figure 4.2:10.  Site-directed mutagenesis of CD31 cytoplasmic domain shows 
conserved downstream lysines K85 and K86 are required for Hsp90 binding.  The blot 
was reprobed for SHP-2 to confirm correct folding of the constructs, and again for 















































Utilising the CD31 cytoplasmic domain constructs already available (Y633F, Y686F, 
Y663F/Y686F, Y701F and QSA), Hsp90 was shown to bind independently of the 
ITIM tyrosines and the serine residues, and hence tyrosine phosphorylation of the 
cytoplasmic domain of CD31.  Examination of the sequence alignment of the CD31 
cytoplasmic domain with other Hsp90 binding proteins, revealed conserved regions; 
in particular the possibility of the cytoplasmic domain containing a TPR motif.  
Truncation of the cytoplasmic domain to perturb the potential TPR and other 
conserved residues revealed multiple binding sites for Hsp90.   
CD31 has been shown to bind calmodulin in platelets 163, and Hsp90 binds to 
calmodulin in complex with the glucocorticoid receptor162.  Truncations containing 
the calmodulin binding site (KAFYLRKAKAK) were able to bind Hsp90 and 
possibly mediate an indirect interaction, but truncations missing this region were not.  
From GST pulldowns (Chapter 2) and subsequent MALDI-TOF analysis of low 
molecular weight proteins, calmodulin was not found binding to CD31 in the system, 
neither has calmodulin been found by CD31 crosslinking studies and subsequent 
Western blotting (personal communication, Dr Simon Brown, University of 
Edinburgh, UK). 
From pulldown experiments using a further set of truncations a region of the CD31 
cytoplasmic domain downstream from the calmodulin binding region containing the 
sequence (SNNEKMSDMEANSHY) was identified as being required for Hsp90 






when the constructs were able to bind SHP-2, which suggested phosphorylation and 
subsequent SHP-2 recruitment may compete with Hsp90 for binding of the 
cytoplasmic domain of CD31.  
These findings raised the possibility of there being a TPR motif in the cytoplasmic 
domain of CD31, therefore site-directed mutagenesis was used to change the basic 
charge of  key amino acids within the TPR motif  to determine whether Hsp90 
binding to the cytoplasmic domain of CD31 conformed to consensus TPR binding 
interactions.  
The most conserved region of CD31 (when compared to the other Hsp90 binding 
proteins that also contain a TPR) SNNEK, was subjected to site-directed 
mutagenesis, at the first N (asparagine 27), and K (lysine 30). Mutating this residue 
from asparagine to alanine abrogated Hsp90 binding, but changing this residue to 
aspartic acid allowed Hsp90 association.  This apparent discrepancy may be due to 
the mutation involving aspartic acid altering the structure of the cytoplasmic domain 
of CD31 allowing Hsp90 to utilise the first asparagine of the SNNEK motif (N 26) 
and thus still bind.  Changing the basic amino acid that was most conserved (lysine 
30) to an alanine did not prevent Hsp90 binding to the cytoplasmic domain of CD31.  
A further downstream conserved lysine at amino acid position 64 allowed Hsp90 
binding, however two further lysines at 85 and 86 (85 is part of the putative 
carboxylic clamp) were also targeted by site directed mutagenesis, and prevented 






These data suggest that this region of the cytoplasmic domain of CD31 could 
conform to a TPR motif. However, there were some caveats to the results.  The 
conserved residues targeted were postulated to contain a TPR motif, and mutations of 
these were thought to prevent Hsp90 binding.  As not all conserved residue mutation 
prevented Hsp90 binding, perhaps single amino acid changes are insufficient to 
perturb the structure of CD31 so that Hsp90 is unable to bind.  Double mutations of 
both the postulated TPR and carboxylic clamp of CD31 are required to examine this 
possibility. 
To explore the functional consequences of this interaction, particularly in the context 
of CD31-mediated migration, constructs of the cytoplasmic domain that do not bind 
Hsp90 (CD31TMΔ37,81, CD31TMΔ31,87 and CD31TMΔ41,77) could be 
introduced into CD31 negative Jurkats and their ability to transduce motility signals 
measured in the detachment assay.   
There is a possibility that the association of Hsp90 with the cytoplasmic domain of 
CD31 may be due to its function as a chaperone, and could be recognising the GST 
constructs as being improperly folded.   However, as particular regions of amino 
acids of the cytoplasmic domain of CD31 seem to be required for Hsp90 binding, 
perhaps CD31 is a client of Hsp90 and Hsp90 is required for the maturation of the 
receptor.  Hsp90 may also be using CD31 as a scaffold to bring src kinases to the 



















5.1 General Discussion 
CD31 is an immunoglobulin superfamily member involved in the process of 
mediating leukocyte transmigration to sites of inflammation.  The work in this thesis 
set out to test the hypothesis that there is differential recruitment of signalling and 
adapter molecules to the cytoplasmic domain of CD31 in viable and apoptotic 
leukocytes.  In addition, we have attempted to ascertain the role of cytoplasmic 
binding partners for CD31 in viable leukocyte attachment to macrophages, and their 
subsequent detachment. 
To explore the role of CD31 in leukocyte detachment from macrophages, we 
screened a panel of leukemic cell lines expressing CD31 for their ability to attach to 
the myelomonocytic cell line THP-1 that had been differentiated into a ‘macrophage-
like’ phenotype.   
Neither MM6, U937 nor KG-1 cells attached to the THP-1 in a temperature 
dependent manner.   Jurkats stably transfected with wild-type CD31, exhibited less 
ability to attach to the THP-1 than Jurkats negative for CD31 84.  Thus, although the 
binding at room temperature observed with both CD31 positive and CD31 negative 
Jurkats was similar, only CD31 positive cells showed temperature-dependent 
attachment at 37˚C.  This observation implies that CD31 is mediating signalling in 
the Jurkat to permit active disengagement from the THP-1.   
 
Experiments using CD31 positive Jurkats with double tyrosine mutations in the ITIM 






viable Jurkats. This finding implied that signalling molecules involved in mediating 
the detachment signal require the ITIM intact.  Molecules that bind to the 
cytoplasmic domain of CD31 via the ITIM include the protein tyrosine phosphatases 
SHP-1 and SHP-2.  Experiments examining the attachment at room temperature with 
cells having single tyrosine mutations demonstrated that Y663F Jurkats exhibit 
temperature-dependent attachment. SHP-2 has been shown to preferentially bind to 
Y686 63, and therefore act as a docking protein for downstream signalling molecules 
involved in motility.  Consistent with this argument, the lack of temperature-
dependent binding observed with Y686F Jurkats could be explained by the loss of 
SHP-2 binding to Y686, and consequently a failure to activate downstream signalling 
pathways.   
There has been some controversy surrounding the role of the ITIM of CD31 and 
what role it plays in mediating migration of endothelial cells.  Wound healing 
migration was impaired when endothelioma cells were transfected with a CD31 
ITIM mutant, suggesting CD31 requires the ITIM to recruit SHP-2 and consequently 
may regulate focal adhesion turnover by dephosphorylating FAK during migration 59.  
A similar study with a lung endothelial line showed cells transfected with an ITIM-
deficient CD31 had increased migration, implying that recruitment of SHP-2 to the 
ITIM acted like a ‘brake’ to regulate migration.  Increased β-catenin phosphorylation 
was also observed which could have loosened adherens junctions and enhanced 
migration 60.  However, another study by the same group61 showed transfection of a 
mesothelioma cell line with an ITIM mutant CD31 made no difference to the ability 






Instead, they showed that migration was dependent on a balance between Rac and 
Rho activity, with Rho activity required for the production and extension of 
lamellipodia. The work presented in this thesis suggests the ITIM of CD31 has a 
positive role in mediating leukocyte migration, which may allude to CD31 having 
different functions in leukocytes compared with endothelial cells.   
 
Both SHP-1 and SHP-2 were targeted pharmacologically by the selective 
phosphatase inhibitor sodium stibogluconate.  At 10µg/ml stibogluconate SHP-1 
activity is blocked, and at 100µg/ml SHP-2 activity is inhibited 172.  Overall, 
attachment was unaffected at either concentration of the drug, but there was some 
inconsistency between results from each individual assay.  The efficacy of the drug 
treatment was not tested, and this could be the reason for the variability.  
Specifically targeting SHP-2 in Jurkats with siRNA to knock-down protein 
expression would confirm the role of the phosphatase in mediating leukocyte 
attachment to macrophages.  SHP-2 could be acting as a docking protein for 
downstream signalling molecules, or could be involved in dephosphorylating CD31 
to allow binding of alternative proteins that are normally inhibited from interacting 
with tyrosine phosphorylated CD31. 
 
Having demonstrated that CD31 has a role in leukocyte motility in vitro, an in vivo 
model could have been developed.  A model of leukocytes disappearing in the 
murine GOLO (greater omental lymphoid organ) has been used in this laboratory.  






wild-type or CD31KO mice, more CD31 wild-type thymocytes were recovered in 
lavages than CD31KO thymocytes showing CD31 is mediating thymocyte 
detachment from peritoneal macrophages. The model could be adapted to target 
specific candidate molecules, such as SHP-2, by siRNA prior to injection into the 
mouse. 
 
We postulated CD31 may be recruiting SHP-2 to the ITIM, where SHP-2 in itself 
acts as a docking protein for other SH2 domain containing proteins downstream that 
leads to the activation of Rac.  Rac has been shown to destabilise adherens junctions 
and thus facilitate cell migration 144. 
Investigation with GST pulldowns and subsequent MALDI-TOF analysis revealed 
eIF3 (Elongation initiation factor-3) which is an RNA helicase and myosin, a 
cytoskeletal component bound uniquely to the Y663F/Y686F mutant CD31 
construct, and were not present in the wild type pulldown. These findings suggest 
CD31 may participate in a different signalling pathway in the absence of tyrosine 
phosphorylation.  As CD31 is intimately involved in the turnover of focal adhesions, 
it is possible that CD31 could also contribute to the formation of spreading initiation 
centres (SIC).  SIC have been shown as the precursors to focal adhesions and contain 
RNA and RNA binding proteins and actin 149.   
 
Investigation with GST-CD31 constructs in a GST pulldown assay of Jurkat lysates 
revealed that SHP-1 was able to bind to the cytoplasmic domain of CD31 and that 






also found to bind CD31 via the ITIM tyrosines, with weak association demonstrated 
when either Y663F or Y686F single mutant tyrosine were used as bait, also 
confirming previous findings 62.  The pulldown method required much optimisation, 
to reproducibly demonstrate CD31 interaction with cytoplasmic proteins.  When the 
original published method was used60, high levels of  non-specific binding to the 
GST tag were found.  Removing non-specific binding required the cell lysate to be 
precleared with glutathione-agarose beads, and the presence of a detergent in the 
lysis buffer, in addition to extensive washing.    
A number of proteins were screened by GST pulldowns and Western blot that were 
thought to bind to the cytoplasmic domain of CD31 and be involved in downstream 
signalling from SH-2 domain containing proteins.  Interestingly, p120 RasGAP was  
found not to bind to the recombinant CD31 protein. However, RasGTP was recently 
found to bind to a Δexon15 isoform of CD31 in endothelial cells, and transduce 
intracellular signalling by activating ERK (extracellular signal-regulated kinase) and 
MAPK (mitogen-activated protein kinase)70.  During leukocyte extravasation through 
the endothelium, ERK and MAPK activation is necessary for the leukocyte to 
migrate, as inhibiting the activation of these signalling molecules does not allow 
migration to take place173.It could be that although the effector molecule RasGTP is 
capable of binding CD31, the guanidine exchange factors themselves may not 
associate directly with CD31. 
β-catenin has been shown to bind to tyrosine phosphorylated CD31 in endothelial 
cells, where CD31 plays a role in the cycling of β-catenin from endothelial cell 






β-catenin, which then dissociates from CD31 allowing it to rejoin the adherens 
junction 65.  It was postulated that the interaction of β-catenin with CD31 may also 
occur in leukocytes and hence be involved in a signalling pathway during leukocyte 
migration. However, GST pulldowns analysis failed to demonstrate β-catenin 
binding to the cytoplasmic domain of CD31, which implies that β-catenin may have 
a different function in leukocytes compared with endothelial cells.   
 
CD31 has been shown to be phosphorylated  by src family kinases 54, and prior to use 
in pulldown analyses the GST-CD31 constructs required phosphorylation in vitro by 
recombinant c-src.  Since the GST-CD31 constructs were not phosphorylated either 
when produced in the bacteria or in the cell lysate, and consistent with previous 
observations with endothelial CD31 showing CD31 is phosphorylated by src, but a 
GST-CD31 cytoplasmic domain fusion protein did not co-precipitate with src 54. 
Results obtained by GST pulldown from Jurkat lysates demonstrated there was no 
binding of c-src to the cytoplasmic domain of CD31. 
 
CD31 activates β1 integrins during transendothelial migration of T cells 4.  Talin 
binds to both the β1 integrin cytoplasmic domain and actin, thereby linking integrins 
to the actin cytoskeleton, thus talin binding can modulate integrin function.  It had 
been suggested that CD31 binds talin via the cytoplasmic domain (personal 
communication, Dr David Critchley, Leicester University, UK), and CD31 might 
activate integrins via its association with talin.  A study with NK cells showed talin 






However, investigation with GST pulldowns from Jurkat lysates did not confirm 
talin binding to the cytoplasmic domain of CD31. These data suggest although talin 
may be involved in CD31 induced integrin activation, it does not bind directly to 
CD31 cytoplasmic domain. 
 
As previously shown, SHP-2 in apoptotic Jurkats was degraded in a caspase-
dependent manner, whereas SHP-1 levels remained unchanged when compared with 
viable Jurkat lysates 84.  In order to test the hypothesis of differential recruitment of 
signalling and adapter molecules to the cytoplasmic domain of CD31, attempts were 
made to induce apoptosis in CD31 negative Jurkats.  However, this proved 
problematic, with the treatments of Fas ligand, etoposide and cycloheximide 
inducing a high proportion of necrotic cells (20-60%) with low levels (<20%) of 
apoptosis.  It was decided to use neutrophils as an alternative as they undergo 
constitutive apoptosis with little necrosis during overnight culture.  Surprisingly, 
comparison of binding partners of CD31 in lysates of viable and aged neutrophils 
showed no change in SHP-1 or SHP-2 levels in binding to CD31 cytoplasmic domain 
in freshly isolated or aged neutrophils.  However, the tyrosine phosphorylation levels 
of the cytoplasmic domain construct were decreased in aged neutrophils, which 
suggested there may be increased phosphatase activity in apoptotic neutrophils.  
CD31 dephosphorylation  in neutrophils may be due to altered utilisation of 
signalling pathways during apoptosis, as shown in endothelial cells undergoing 
programmed cell death CD31 is dephosphorylated, resulting in the cellular 







In preliminary studies by others in the laboratory, the 90kDa heat shock protein 
(Hsp90) has been shown to bind to CD31.  The work undertaken in this thesis set out 
to elucidate which residues of the cytoplasmic domain of CD31 were important for 
the interaction with Hsp90.  GST pulldowns from CD31 negative Jurkat lysates with 
the CD31 constructs Y663F, Y686F and Y663F/Y686F showed that the ITIM, and 
hence by inference tyrosine phosphorylation of the ITIM, was not required for Hsp90 
binding.  Pulldowns using a series of truncations of the cytoplasmic domain revealed 
two distinct regions that were required for Hsp90 binding, (CYFLRKAKAK) and 
(SNNEKMSDMEANSHY). (CYFLRKAKAK) has previously been shown to be a 
calmodulin binding region in platelets 163, and Hsp90 binds to calmodulin in complex 
with the glucocorticoid receptor 162.  This finding raises the possibility that Hsp90 
may be binding to CD31 indirectly through calmodulin bound to CD31.  However, 
analysis of low molecular weight bands (~17kDa) present in GST pulldowns of 
Jurkat lysates with MALDI-TOF failed to identify calmodulin.  Repeating the GST 
pulldowns with non-phosphorylated truncated CD31 constructs showed no binding 
of Hsp90 to CD31, which suggested that Hsp90 requires the cytoplasmic domain 
tyrosine phosphorylated independently of the ITIM.  There are two tyrosines 
upstream of the ITIM of CD31, Y596 and Y636, which could be phosphorylated and 
either bind an intermediary protein, or bind Hsp90 directly.  However, Y595 did not 
need to be phosphorylated to bind calmodulin 163, which would further suggest that 
the intermediary protein may not be calmodulin.  The same study also showed a 






which adds weight to the suggestion that the intermediary protein is not calmodulin.  
Generating further mutations of CD31 at Y595 and Y636 to probe Jurkat lysates for 
Hsp90 binding would determine whether these residues are crucial for Hsp90 
association and help us to identify if an intermediary protein is also required. 
The region (SNNEKMSDMEANSHY) was also required for Hsp90 binding to 
CD31, containing the conserved region SNNEK which potentially could represent a 
helix region of a putative TPR motif.  Further exploration of the TPR motif via site-
directed mutagenesis of the basic amino acids revealed that whilst mutation N27A 
abrogated Hsp90 binding, mutating N27 to D did not prevent Hsp90 binding.  This 
may be due to an alteration to the structure of the cytoplasmic domain of CD31 
allowing Hsp90 to utilise the first asparagine of the SNNEK motif (N 26) and thus 
still bind.  Downstream mutation of basic lysine residues 85 and 86 also prevented 
Hsp90 binding. These residues are postulated to be part of the carboxylic clamp 
which acts in concert with the TPR to mediate protein binding.  The data presented 
here leaves open the possibility of the cytoplasmic domain of CD31 conforming to a 
TPR motif, however double mutations of both the TPR and carboxylic clamp would 
be necessary to confirm this.  
The functional consequences of Hsp90 binding to CD31 were not explored in this 
work, for example the possibility of a role for CD31-Hsp90 interaction during 
leukocyte motility. Jurkats could be transduced to express CD31 with mutations in 
the regions required for Hsp90 binding identified here, and then assayed for the 







As well as probing GST pulldowns for suspected CD31 binding partners, we also 
chose a non-biased approach of MALDI-TOF protein fingerprinting. By separating 
the GST pulldowns by SDS-PAGE and targeting unknown proteins we hoped to 
discover novel binding proteins of CD31.  Of the proteins identified by this method, 
14-3-3ε was of particular interest. 14-3-3ε is a member of the large family of 14-3-3 
proteins which have diverse roles in cellular processes including ligand binding and 
protein localisation.  This protein has been described as a ‘molecular anvil’ that binds 
proteins and changes their conformation enabling them to participate in intracellular 
signalling 148.  14-3-3 proteins also bind SH-2 domain containing proteins 148, and 
could be participating in signalling through binding CD31 directly or by binding 
SHP-2 associated with CD31.    
CD31 has been shown recently to activate a non selective cation channel, in response 
to hydrogen peroxide in endothelial cells.  The regulation of ion channel function 
requires an intact cytoplasmic domain, as well as an intact ITIM, as mutation of the 
CD31 ITIM resulted in no activation 175.  Recent work in this laboratory has shown 
CD31 may be capable of inhibiting the repolarisation of macrophages through the 
potassium channel HERG (human ether-a-go-go related gene) following a 
depolarising stimulus (Brown et al. 2006 submitted). The adapter protein 14-3-3ε 
also binds to PKA phosphorylated HERG, and is involved in stabilising the HERG 
phosphorylation state.  14-3-3ε binds as a dimer by protecting HERG from the action 
of phosphatases which function to decrease HERG activity and enhance the activity 
of HERG, 176.  The data from GST pulldowns and MALDI-TOF studies raises the 






are activated by CD31 during leukocyte transmigration 6.  Since HERG has been 
shown to be physically linked to β1 integrins, and modulate their activation 177, CD31 
could be regulating HERG to allow integrin activation during leukocyte migration.  
Also of interest given the finding of association between Hsp90 and CD31 is the 
requirement of HERG for the chaperone Hsp90 probably in complex with Hsp70 and 
other co-chaperones for HERG folding and maturation 178. 
 
Although the function of the signalling and adapter molecules alluded to in this work 
have not been elucidated, they nevertheless suggest a number of novel and 
potentially exciting pathways to pursue.  Particularly the possibility of CD31 in 
viable leukocytes, upon ligation of CD31 forming a macromolecular complex that 
will encompass different signalling and adapter molecules dependent on the tyrosine 
phosphorylation state of CD31, which could have implications for leukocyte 
migration (Figure 5.1:1).  Phosphorylation of the ITIM tyrosines of CD31 recruits 
SHP-2, which could act as a docking protein for the recruitment of the SH2-domain 
containing protein Grb2.  Grb2 may bind Gab1 and then associate with DOCK180 
bound to ELMO.  This complex could promote the activation of Rac and drive the 
formation of membrane ruffles and lamellipodia, and thus motility of the cell.  The 
adapter protein 14-3-3ε may have multiple roles in cellular function, and as it is 
capable of binding to HERG and β1 integrins, and may provide a mechanism for 
CD31-mediated activation of integrins and adhesion during the early stages of 
transmigration.  Hsp90 may be acting as a transporter for src kinase movement to the 






tyrosines 596 and 636.  Hsp90 is required for HERG maturation 148, and has also 














Figure 5.1:1.  CD31 may be forming a macromolecular complex in viable leukocytes.  
A signalling pathway through SHP-2 binding to phosphorylated ITIM tyrosines and 
acting as a docking protein for the binding of SH2 domain containing proteins Grb2 
and Gab1 which bind DOCK180, an exchange factor of Rac, which could regulate the 
activation of Rac.  Hsp90 binding of CD31 through the potential association of an 
unknown intermediary protein may serve as a chaperone or transporter of src kinase, 





























5.2 Future Work 
In view of the results presented in this thesis, future work with the attachment assay, 
in particular the use of siRNA delivered by lentivirus to target SHP-2, would be of 
major importance.   Knocking-down the expression of SHP-2, and thus preventing 
the postulated signalling pathway from taking place, we would have expected to see 
a defect in temperature dependent attachment of viable CD31-expressing Jurkats to 
the THP-1 monolayer.  To extend the attachment assay, the development of a 
suitable in vivo model of leukocyte attachment would be an important goal.   A 
model of murine leukocyte-macrophage interactions in the GOLO has been used by 
others in this laboratory. Preliminary experiments introducing either wild-type or 
CD31 knock-out thymocytes into the GOLO have shown better recovery of wild-
type thymocytes than knock-out (Dr Simon Watson, personal communication).  This 
model could be adapted to knock-down SHP-2 expression in murine thymocytes, and 
assay the recovery of the thymocytes, where we would expect a defect in migration 
and more recovery.  We would predict that SHP-2 phosphatase-dead mutant 
thymocytes in this assay exhibit reduced migration and thus confirm the in vitro 
findings presented here. 
 
Data from GST pulldowns showing Hsp90 binding to CD31 provided biochemical 
evidence of an interaction between the two proteins, and further mutations of CD31 
of both the postulated TPR motif and the carboxylic clamp region could be generated 






Hsp90 with the cytoplasmic domain of CD31 may shed light on the question of 
Hsp90 involvement in mediating migration signals. Transducing Jurkats negative for 
expression of CD31 with constructs missing key residues identified by this work and 
then assaying their ability to attach to THP-1 cells, we expect to see an attachment 
defect if Hsp90 is either directly involved in a signalling pathway or is required for 
the correct folding of CD31.  As has been postulated in this thesis, SHP-2 signalling 
through its association with CD31 may represent a critical event in providing viable 
leukocyte detachment signals.  Generating a SHP-2 construct to use in GST 
pulldowns, both wild-type and a catalytic mutant, would then allow detailed 
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6.1 MOLECULAR BIOLOGY 
6.1.1 E. coli Competent Cell Preparation 
A single colony from an LB plate was picked and grown up in 2.5ml LB medium at 
37°C with shaking overnight.  The culture was diluted 1:100 in fresh LB 
supplemented with 1M MgSO4 and grown at 37°C with shaking until the OD600nm 
read between 0.4 and 0.6.  Cells were centrifuged at 4500g at 4°C for 5 minutes.  The 
cell pellet was resuspended in 0.4 volume ice-cold filter-sterilised TFB1 buffer pH 
5.8. The cells were centrifuged again and resuspended in 0.25-volume ice-cold filter-
sterilised TFB2 pH 6.5 for 30 to 60 minutes.  Cells were aliquoted and quick-frozen 
in liquid nitrogen before storage at -70°C. 
 
6.1.2 Polymerase Chain Reaction (PCR) 
CD31 Products were amplified from constructs in pcDNA3, for details of primer 
sequences, restriction sites added and PCR programme see Appendix. 
 
6.1.3 Cloning 
The amplified fragments were ligated into pGEMTeasy (Promega), by virtue of the 
overhanging A bases added by Taq polymerase during amplification.  The ligations 
were transformed into DH5α competent E. coli cells and colonies selected on LB 
agar supplemented with ampicillin 100mg/ml overnight.  Positive colonies were 
selected based on blue/white screening, where the addition of an insert into 
pGEMTeasy vector disrupts the β-lactimase gene, resulting in no metabolism of the 
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ampicillin 100μg/ml with shaking overnight at 37°C.  Plasmid DNA was extracted 
using a kit (Qiagen) and digested with Bam HI and Sal I restriction enzymes.  The 
resulting digest was separated on 1% agarose gel and the fragment extracted from the 
agarose (Qiagen). 
The digested DNA fragments were cloned into pGEX vector containing a 
glutathione-S-transferase (GST) sequence, transformed into XL-1 blue competent 
cells and selected on LB agar supplemented with ampicillin 100mg/ml.  Single 
colonies were picked and the plasmids extracted as described.  Purified plasmids 
were sequenced with the primers described in Table 7.1:10. 
 
6.1.4 Site-directed Mutagenesis of CD31 
Primers were designed to introduce the mutation required into CD31.  PCR was 
carried out on wild-type CD31 in pcDNA3 as described to generate a super primer, 
which is 100-200bp double-stranded DNA (Table 7.1:10).  The super primer was 
then ran on 1% agarose gel and purified using Qiagen gel purification kit. The super 
primer is then used in PCR with proof-reading DNA polymerase Pfu Turbo to 
replicate the whole plasmid.  The reaction was digested with 2µl Dpn I, 8µl 10X 
buffer and 20µl distilled water for 6 hours to remove methylated original DNA 
template.  The reaction was heat-inactivated at 65˚C for 10 minutes and cooled at 
room temperature for 10 minutes.  8µl of the reaction was used to transform 100µl 
chemically competent E. coli.  Single colonies were picked into LB medium 
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were carried out to purify the mutated plasmid DNA and the mutation was confirmed 
by sequencing. 
 
6.1.5 Reconstitution of Plasmid DNA from Filter Paper 
The plasmid on filter paper was added to 300µl distilled water and incubated at room 
temperature for 10-15 minutes.  The tube was centrifuged at 13000rpm for 3 minutes.  
5µl of the reconstituted DNA was transformed into JM109 chemically competent 
bacteria and plated onto LB-agarose supplemented with 100µg/ml ampicillin 
overnight at 37˚C. 
 
6.1.6 Chemically Competent Bacteria Transformation 
An aliquot of competent E. coli was allowed to thaw on ice.  In a separate Eppendorf, 
2-5μl of ligation mix was transferred, and mixed with the thawed bacteria, on ice for 
30 minutes.  The cells were heat shocked for 1 minute and then returned to ice for 2 
minutes.  400μl SOC media was added and the cells incubated at 37˚C with shaking 
for 30 minutes.  The cells were centrifuged at 200g for 4 minutes and the media 
discarded.  The cells were plated onto LB-agarose supplemented with ampicillin 
100μg/ml overnight at 37˚C. 
 
6.1.7 Bacterial Glycerol Stock Preparation 
A single colony from a selection plate was picked into 2ml LB medium 
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overnight.  1ml of the culture was added to 80% glycerol and mixed.  The stock was 
stored at -80˚C. 
 
6.1.8 Electroporation of Competent Bacterial Cells 
An aliquot of electrocompetent BL21 E. coli cells were defrosted on ice and 2μl of 
ligation mix were added to the cells and mixed.  The cells and DNA were transferred 
to an electroporation cuvette and the pulse was triggered with the following 
parameters employed: Voltage 2500V, capacitor 25μF and shunt resistor 201R.  1ml 
of SOC medium was added, and the cells were transferred into an Eppendorf and 
incubated at 37°C with shaking for 30 minutes.  The cells were plated onto LB-
agarose supplemented with 100μg/ml ampicillin and incubated at 37˚C overnight. 
 
6.2 RNA Methods 
6.2.1 RNA Isolation 
1ml of Trizol was added per 5 million cells and the cells were homogenised, then 
incubated at room temperature for 5 minutes and 200µl of chloroform was added. 
The tube was shaken vigorously for 15 seconds, and incubated at room temperature 
for 5 minutes. The tube was centrifuged at 12000g and 4˚C for 15 minutes to 
separate the phases.  The aqueous phase was transferred to a fresh tube and 500µl 
Trizol and 200µl chloroform was added.  The tube was shaken vigorously for 15 
seconds and incubated at room temperature for 5 minutes. The tube was centrifuged 
at 12000g and 4˚C for 15 minutes to separate phases.  The aqueous phase was 




Materials and Methods 
150
at room temperature for 15 minutes and centrifuged at 12000g at 4˚C for 10 minutes.  
The supernatant was removed and 1ml 75% ethanol was added and the tube shaken 
vigorously.  The tube was centrifuged at 7500g for 5 minutes.  The supernatant was 
removed completely and the pellet was allowed to dry. The pellet was resuspended in 
DEPC treated distilled water. 
 
6.2.2 Conversion of RNA to cDNA  
To each reaction tube 5µl of 10X reverse transcription buffer, 11µl 25mM MgCl2, 
10µl dNTPs, 2.5µl random hexamers, 1µl RNAse inhibitor, 1.25µl reverse 
transcriptase and 200ng RNA was added.  The volume was made up to 50µl with 
RNAse-free distilled water.  The reaction was incubated in a PCR machine with the 
following programme: 25˚C for 10 minutes and 95˚C for 5 minutes. 
 
6.2.3 siRNA Delivery by Electroporation of Jurkats 
SHP-2 and lamin A/C RNA was prepared according to the manufacturer’s 
instructions and 2µg was transfected into 1 million CD31 positive Jurkat cells using 
Amaxa protocol A17.  The cells were incubated at 37˚C and 5% CO2 for 24, 48 and 
72 hours.  Knock-down was analysed by western blot. 
 
6.2.4 siRNA Construction for Lentiviral Delivery in Jurkats 
siRNA short hairpin constructs were generated with Sal I and Hind III restriction 
sites at both 5’ and 3’ end, and containing a loop TCAAGAG for insertion into 
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Name siRNA Sequence 






















Table 6.2:1.  Sequence of siRNA sense and antisense strands for SHP-2, lamin A/C 
and scrambled including the Sal I restriction site at both 5’ and 3’ ends, and in bold 
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6.3 Protein Chemistry  
6.3.1 Preparation of Agarose Beads 
100µl (GST pulldowns) or 500µl (protein purification) of glutathione-agarose beads 
(Amersham, Bucks, UK) were washed twice with 500µl/2.5ml of PBS, the 
supernatant was cleared by centrifugation at 500g for 5 minutes and discarded.  Cell 
lysate or recombinant protein was added directly to the prepared beads. 
 
6.3.2 GST Fusion Protein Purification 
A single colony from a transformation plate was picked into 20ml LB supplemented 
with 100μg/ml ampicillin and grown overnight at 37°C with shaking.  The culture 
was diluted 1:10 in LB and 100μg/ml ampicillin and grown for 60 minutes at 37°C 
with shaking. 0.1mM IPTG was added and the culture grown for 3 to 5 hours.  The 
cells were pelleted at 4000rpm for 20 minutes at 4°C.  The pellet was resuspended in 
10ml 1% Triton-X100/PBS buffer on ice.  The cells were sonicated at 50% power for 
four pulses of 30 seconds in duration.  Trypan blue staining checked lysis, with lysed 
cells turning blue.  The cell lysates were centrifuged at 20000g for 30 minutes at 4°C 
and the supernatant transferred to a fresh tube.  A 50% solution of 25mM Tris, 
140mM sodium chloride and glutathione-agarose beads (Sigma) was added to the 
supernatant and rotated for 30 minutes at 4°C.  The sample was centrifuged at 500g 
for 5 minutes and the supernatant discarded.  The beads were washed with PBS three 
times and the GST fusion protein was eluted with 1ml elution buffer rotating for 10 
minutes at room temperature.  The elution was repeated twice.  Eluted fractions were 
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6.3.3 Purification of His-talin  
The His-talin protein was purified using a Magnehis kit (Promega). A 1ml 3 hour 
culture of transformed BL21 bacteria was read at OD600 and centrifuged at 10000g 
for 2 minutes and the supernatant discarded.  For every 1 OD600 unit, the supplied 
lysis buffer was diluted ten times with ultrapure water, and added to the bacteria 
pellet.  1µl DNAse was added and the mixture incubated at room temperature with 
shaking to lyse the bacteria.  0.3g/ml NaCl was added to improve the magnetic bead 
binding to the his-tagged protein.  30µl of his-nickel beads were added per 1.1ml 
lysate, and mixed for 2 minutes.  The tubes were placed against a magnetic stand to 
capture the magnetic beads.  The supernatant was carefully removed with a pipette.  
The beads were washed three times with supplied wash buffer.  The purified protein 
was eluted from the beads incubating for 2 minutes at room temperature in supplied 
elution buffer containing 500mM imadazole. 
 
6.3.4 His-talin Pulldown in Capture Buffer 
50µg of purified his-talin was added to CD31 positive Jurkat lysates and incubated 
with rolling at 4˚C for 30 minutes.  100µl his-nickel magnetic beads were added and 
incubated at 4˚C with rolling for 2 minutes.  The beads were washed three times in 
500µl capture buffer for 2minutes. The beads were resuspended in 100µl elution 
buffer, a total of three times.  The eluate was precipitated overnight in 95% ethanol at 
-20˚C.  The precipitate was centrifuged at 5000g for 10 minutes and the pellet air 
dried.  50µl of sample buffer was added to resuspend the pellet and then boiled for 5 
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6.3.5 Pre-optimised GST Pulldown Assay 
All steps were performed at 4°C with rotating.  100μg of GST-CD31 protein were 
added to cell lysates for 30 minutes.  500μl of 50% glutathione-agarose beads/PBS 
were added for 30 minutes.  The beads were pelleted at 500g for 2 minutes at 4°C 
and then washed in 500μl GST pull-down buffer for 30 minutes.  The beads were 
pelleted at 500g for 2 minutes then the protein eluted using 500μl elution buffer, 
rotating at room temperature for 10 minutes.  The eluted protein was precipitated in 
95% ethanol overnight at -20˚C.  The precipitated protein was centrifuged at 15000g 
for 10 minutes at 4˚C, the ethanol removed and the pellet dissolved in 50μl Laemmli 
sample buffer, with vortexing.  The sample was boiled for 5 minutes before loading 
onto 10% reducing SDS Tris-glycine gel.   
 
6.3.6 Recombinant Protein Coupling to Beads 
10µg of recombinant GST or GST-CD31 protein was added to prepared glutathione-
agarose beads and rolled at room temperature for 30 minutes.  The beads were 
washed with 500µl of PBS and centrifuged at 500g for 5 minutes to remove unbound 
protein. Cell lysate was added directly to the prepared beads in accordance with the 
protocol. 
 
6.3.7 Method 1 GST Pulldown 
The beads were combined with recombinant protein and the lysate added with rolling 
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supernatant discarded.  The beads were washed three times in lysis buffer and 
resuspended in sample buffer before being loaded onto a 10% reducing SDS-PAGE 
gel. 
 
6.3.8 Method 2 GST Pulldown 
The cell lysate was precleared with 100µl glutathione-agarose beads overnight at 
4˚C.  The beads were centrifuged at 500g and the supernatant removed, then added to 
recombinant protein coupled to fresh glutathione beads and rolled at 4˚C for 2 hours. 
The beads were washed three times in lysis buffer and once in PBS, then the beads 
were resuspended in 50µl PBS before being combined with an equal volume of 
sample buffer and boiled and applied to a 10% reducing SDS-PAGE gel. 
 
6.3.9 Method 3 GST Pulldown 
Glutathione-agarose beads were combined with recombinant protein and added to the 
cell lysate at 4˚C with rolling for 2 hours.  IP buffer was added and the mixture rolled 
for another 2 hours.  The beads were centrifuged at 500g and the supernatant 
discarded.  The beads were washed once with IP buffer and resuspended in sample 
buffer before being applied to a 10% reducing SDS-PAGE gel. 
 
6.3.10 In vitro Phosphorylation 
10µg recombinant protein was combined with 0.01U recombinant src kinase, 1µM 
ATP to a total volume of 50µl with phosphorylation buffer, and incubated at room 




Materials and Methods 
156
 
6.3.11 Preparation of Protein Samples for MALDI-TOF 
GST pulldowns were prepared as described, and lyophilised.  The sample was 
reduced with 60μl of reducing sample buffer, vortexed and incubated at 70˚C for 10 
minutes. In a laminar flow hood, the sample was separated by electrophoresis on a 4-
12% MOPS-SDS gradient gel at 200mV for 1 hour.  The gel was washed three times 
with deionised water and stained with colloidal blue stain with rocking for 1 hour at 
room temperature.  The gel was destained three times with deionised water.  The 
bands of interest were excised from the gel and chopped into small pieces.  250μl of 
100mM ammonium bicarbonate was added to each gel piece, and the gel pieces were 
shaken for 15 minutes.  The liquid was removed from the gel pieces and 250μl 50% 
acetonitrile was added for 10 minutes with shaking.  The liquid was the removed and 
the gel pieces dried by speed vacuum.  50μl DTT dissolved in 100mM ammonium 
bicarbonate was added and the gel pieces incubated at 56˚C for 1 hour.  50μl of 
9.25g/ml iodoacetamide solution was added and the gel pieces were incubated in the 
dark at room temperature for 30 minutes.  The liquid was removed and 200μl 
ammonium bicarbonate were added for 15 minutes at room temperature with 
shaking.  The liquid was removed and 200μl 50% acetonitrile were added at room 
temperature with shaking.  30μl of trypsin buffer were added to the gel pieces plus 
10μl of trypsin solution (12.5μg/ml trypsin and 1mM HCl in ammonium 
bicarbonate).  Incubate the reaction at 30˚C overnight with shaking.  Centrifuge 
sample to collect gel pieces and add an equal volume of acetonitrile.  Spot 0.5μl onto 
a sample well of a MALDI-TOF plate and allow to dry before spotting another.  Add 
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6.3.12 Silver Staining of SDS-PAGE gel 
Incubate the gel in solution A for 30 minutes at room temperature.  Wash the gel in 
solution B for 15 minutes then three times in bidistilled H2O.  Sensitise the gel in 
solution C for 2 minutes and wash three times in bidistilled H2O for 30 seconds each 
wash.  Stain for 25 minutes in solution D and wash three times for 1 minute each in 
bidistilled H2O.  Develop in solution E for 5 to 10 minutes and stop in solution F for 
10 minutes.  Rinse the gel in bidistilled H2O. 
 
6.3.13 Western Blotting 
Protein was transferred from polyacrylamide gel onto PVDF membrane at 100V for 
1 hour with ice pack and stirring.  The membrane was blocked in 5% milk/PBS 
overnight at 4˚C, then washed three times in 0.1%Tween 20/PBS for 10 minutes 
each.  The primary antibody was added (SHP-1, SHP-2 1:500, Hsp90 1:500, GST 
1:5000, src 1:1000, β-catenin 1:1000, p120 1:1000, talin 1:1000) diluted in 0.1% 
Tween 20/PBS for 2 hours at 4˚C.  The membrane was washed as described and the 
secondary antibody conjugated to HRP was added at 1:1000, diluted in 0.1% Tween 
20/PBS for 1 hour at 4˚C.  The membrane was washed a further three times in 0.1% 
Tween 20/PBS for 10 minutes each.  ECL plus reagents were added to the 
membrane, and the membrane was exposed to X-ray film and developed in an 
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6.4 Cell Biology  
6.4.1 Cell Culture 
Jurkats and THP-1 were routinely maintained in suspension in RPMI medium 
supplemented with 10% heat inactivated foetal calf serum, 10mM glutamine, 10mM 
penicillin-streptomycin at 37˚C and 5% CO2.   
HEK-293T cells were maintained in DMEM medium supplemented with 10% heat 
inactivated foetal calf serum, 10mM glutamine, 10mM penicillin-streptomycin at 
37˚C and 5% CO2 at 30-50% confluence. To split the cells 5ml trypsin/EDTA was 
added for 5 minutes at room temperature.  The flask was banged to release the cells 
and 10ml of medium was added and pipetted up and down the side of the flask to 
wash cells off.  The cells were then centrifuged at 220rpm for 5 minutes and 
resuspended in fresh media. 
THP-1 were differentiated in an 8-well chamber slide in RPMI with 10ng/ml PMA 
for 5 days.  The cells became adherent and their morphology became spindle-like. 
 
6.4.2 Isolation of Human Neutrophils 
 40ml of freshly isolated venous blood was added to 4ml 3.8% sodium citrate in a 
50ml tube and mixed carefully.  The tube was centrifuged at 12000rpm for 20 
minutes with the brake off.  The supernatant containing protein-rich plasma (PRP) 
was removed and 25ml was reserved. To make serum the remaining PRP was 
aliquoted into glass tubes and incubated with 400µl 1M CaCl2 at 37˚C until the 
solution cleared.  PRP was centrifuged at 300rpm for 15 minutes to provide platelet 
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remaining cells 5ml 6% dextran was added and made up to 50ml with 0.9% NaCl, 
and mixed carefully. The cell mixture was incubated at room temperature for 15-30 
minutes until it separated into two layers. The top leukocyte-containing layer was 
removed and centrifuged at 1000rpm for 6 minutes. The supernatant was discarded 
and the leukocytes were resuspended in 2ml PPP.  Gradients of 42% and 51% 
percoll/PPP were made in separate tubes and vortexed to mix.  The leukocytes were 
underlaid with the 42% gradient then with 51% gradient avoiding bubbles at fluid 
interface.  The gradients were centrifuged at 1000rpm for 10 minutes with the brake 
off, monocytes separated at the top layer, neutrophils at the bottom layer.  The 
neutrophil layer was removed and made up to 50ml with serum-free medium.  The 
neutrophils were centrifuged at 12000rpm for 5 minutes, and the supernatant was 
removed and the neutrophils resuspended in media at a concentration of 4 million 
cells per ml. 
 
6.4.3 Inducing Apoptosis in Jurkats  
Cells were counted and centrifuged at 220g for 5 minutes, the media was discarded 
and the cells resuspended in RPMI without serum and supplemented with 10mM 
glutamine, 10mM penicillin-streptomycin.  1:1000 dilution of CH11 (anti-FasL) 
antibody was added and mixed gently.  The cells were incubated at 37˚C and 5% 







Materials and Methods 
160
6.4.4 Inducing Apoptosis in Neutrophils 
Freshly isolated human neutrophils were resuspended in IMDM media with 10mM 
glutamine, 10mM penicillin-streptomycin in the absence of serum, and incubated at 
37˚C and 5% CO2 overnight.  Apoptosis was measured by annexin V and propidium 
iodide staining. 
 
6.4.5 Attachment Assay 
2 X106 THP-1 were differentiated into 8 well chamber slides as previously described 
over 5 days at 37˚C and 5% CO2 179.  The media was replaced with fresh containing 
no serum.  The cells were stained with 0.1µl of 1mg/ml Celltracker orange for 15 
minutes at room temperature.  1 X 106 Jurkats were counted and resuspended in 4ml 
media without serum and stained with 0.1µl of 1mg/ml Celltracker green for 15 
minutes.  0.5ml Jurkat suspension was added to each of the wells and left to settle for 
15 minutes at room temperature.  The plate was immersed in a bath of prewarmed 
media (37˚C) and inverted under the liquid taking care not to introduce any bubbles.  
The plate was then incubated at 37˚C for 30 minutes.  The plate was turned upright 
and removed from the media bath.  The media was removed and 0.5ml 
trypsin/EDTA added to each well.  The plate was incubated at 37˚C for 15 minutes. 
An equal volume of media was added to each well to neutralise the trypsin.  Cells 
were harvested by pipetting up and down, centrifuged at 500g for 5 minutes and 
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6.4.6 Annexin V and Propidium Iodide Staining 
Cells were centrifuged at 220g for 5 minutes and resuspended in annexin binding 
buffer.  Four tubes were set up as follows, unstained cells, Annexin V-FITC only for 
20 minutes on ice, propidium iodide only and both annexin-V and propidium iodide.  
Propidium iodide was added to the cells immediately before analysis by flow 
cytometry.   
 
6.4.7 CD31-FITC Antibody Staining 
Cells were centrifuged at 220g for 5 minutes and resuspended in 0.5ml FACS buffer.  
CD31-FITC or isotype control IgG-FITC was added at 1:100 dilution of stock, 
incubating on ice for 1 hour.  The cells were centrifuged again and washed with 1ml 
FACS buffer.  Cells were resuspended in 0.5ml FACS buffer and analysed by flow 
cytometry. 
 
6.4.8 Neutrophil Lysis 
50 million neutrophils were lysed in 5ml cell lysis buffer 2 with 2mM levamisole, 
10mM β-glycerophosphate, 10mM NaF, 10mM Na3VO4, and 1 tablet of protease 
inhibitor cocktail (Roche) on ice for 20 minutes. Lysis was confirmed by trypan blue 
staining. The lysate was cleared by centrifugation at 13000rpm for 15 minutes. 
 
6.5 Lentiviral Methods 
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HEK-293T cells at 30-50% confluency (cultured in DMEM with 10% heat 
inactivated foetal calf serum, 10mM glutamine, 10mM penicillin-streptomycin at 
37˚C and 5% CO2), were transfected with plasmid packaging mix. For each 
transfection 1462.7µl of Optimem and 45.3µl FuGene (Roche) were mixed together 
and incubated at room temperature for 5 minutes. 10.2µg of the SHP-2 or SHP-2 C-S 
pLenti plasmid was mixed with 5.1µg of GagPol plasmid (pESYNGP), 2.5µg Rev 
plasmid (pPLP-2) and 0.2µg Env plasmid (pVSV-G). The plasmid mix was added to 
the transfection reagent mix and 1560µl of the resultant mixture was added drop-
wise to each plate of cells. The cells were incubated at 37°C with 5% CO2. For 
vectors containing the CMV enhancer/promoter, 300µl of sodium butyrate was 
added to each plate after 24 hours to induce expression. The medium was changed to 
fresh complete medium (DMEM with 10% FCS, 100mM penicillin-streptomycin, 
10mM glutamine) after 6 hours of incubation at 37ºC. Approximately 16-18 hours 
later, the virus-containing medium was aspirated from the plates and was filtered to 
remove cellular debris using a 150ml filter (0.44µm; Nalgene). The unconcentrated 
virus is then aliquoted into 1ml cryovials and stored at -80˚C. 
 
6.5.2 Lentivirus Transduction of Cells 
1 X106 cells (CD31 negative Jurkats) were centrifuged at 220g for 5 minutes, and 
resuspended in 100µl fresh medium in a 48 well plate.  250µl lentivirus (CD31-
pLenti, SHP-2-pLenti, SHP-2 C-S-pLenti) vector solution was added to the cells and 
mixed.  The cells were incubated overnight at 37˚C and 5% CO2.  300µl of fresh 
media is then added to each well and incubated overnight again.  Approximately 48-
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surface antibody staining (CD31) or by western blotting (SHP-2).  Stable integration 
was confirmed by RT-PCR. 
 
 
6.5.3 X-Gal Staining Solution 
Transduced cells were washed twice with PBS and 500µl of X-gal staining solution 
was added.  The cells were incubated at 37˚C and 5% CO2 for 3 hours before 
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6.6 Buffer Composition 
All reagents were purchased from Sigma unless otherwise stated. 
TFB1 
30mM potassium acetate 
50mM manganese chloride 
10mM calcium chloride  
100mM rubidium chloride  
15% glycerol 




75mM calcium chloride 
10mM rubidium chloride  
15% glycerol 
Adjust pH to 6.5 
 
GST Pulldown Buffer 
50mM Tris 
100mM sodium chloride 
100mM β-mercaptoethanol 
0.5% Tween 20 
 
Laemmli Sample Buffer 
0.6ml 1M Tris-HCl pH 6.0 
5ml 50% glycerol 
2ml 10% SDS 
0.5ml β-mercaptoethanol 
1ml 1% bromophenol blue 
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GST Elution Buffer 
25mM Tris 
140mM sodium chloride  
5mM reduced glutathione 
 
Jurkat Lysis buffer +Tx100 
20mM Tris pH8 
137mM sodium chloride 
2mM EDTA 
1mM sodium fluoride 
1mM sodium pervanadate 
10% glycerol 
1% triton-X 




0.5g Bactoyeast extract 
1ml 1M NaCl 
0.25ml KCl 
1ml 2M Mg2+ stock 
1ml 2M glucose 
Add tryptone and yeast to 97ml deionised water, dissolve and add NaCl and KCl.  
Autoclave and allow to cool before adding glucose and Mg2+ stock.  Filter through 
















5g Bactoyeast extract 
5g NaCl 
Add deionised water to 1 litre.  Adjust pH to 7.5 with NaOH and autoclave. 
 
Trypsin Buffer 
70μl of 1% nog (n-octyl-nβpyranoside)  
630μl of 20mM ammonium bicarbonate solution 
 
TBE Electrophoresis Buffer (10X) 
108g Tris 
55g Boric acid 
40ml 0.5M EDTA 
Make up to 2 litres with distilled water and autoclave. 
 
PAGE Running Gel (10%) 
4ml distilled water 
3.3ml 30% acrylamide 
2.5ml Tris pH 8.8 
100μl 10% SDS 
100μl 10% ammonium persulphate 
4μl TEMED 
 
PAGE Stacking Gel 
2.1ml distilled water 
0.5ml 30% acrylamide 
30μl 10% SDS 







Materials and Methods 
167
Sealing Gel for PAGE 
0.5ml acrylamide 
2ml distilled water 
10μl TEMED 
25μl 10% ammonium persulphate 
 
Coomassie Blue Stain 
0.25g Coomassie blue 
90ml 1:1 v/v methanol/water 









30 g Tris 
5g SDS 






Make up to 1 litre with distilled water. 
 
TE Buffer 











0.05% sodium azide 






Dissolve in PBS 
 






Adjust pH to 7.4 
 





1mM sodium pervanadate 
1mM protease inhibitor cocktail 
(For high salt add 200mM NaCl) 
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Bead Wash Buffer 2 
10mM Tris 
 
GST Pulldown Buffer 1 
20mM Tris 
200mM NaCl 
Adjust to pH8 
 
GST Pulldown Buffer 2 
20mM Tris 
200mM NaI 
Adjust pH to 8 
 
Amido Black Stain 
0.1% amido black 
25% IPA 
10% acetic acid 
 
Amido Black Destain 
25% IPA 
10% acetic acid 
 
Silver Stain Solution A 
100ml 50% methanol 
10% acetic acid  
Prepare in bidistilled H2O 
 
Silver Stain Solution B 
100ml 50% methanol 
 
Silver Stain Solution C 
0.2g sodium thiosulphate 
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Silver Stain Solution D 
200mg silver nitrate 
100ml bidistilled H2O 
Silver Stain Solution E 
3g sodium carbonate 
50µl formaldehyde (37% stock) 
2ml solution C 
Make up to 100ml bidistilled H2O 
 
Silver Stain Solution F 
1.4g sodium-EDTA 
100ml bidistilled H2O 
 
Method 1 Cell Lysis Buffer 






1mM protease inhibitor cocktail 
 
Method 2 Cell Lysis Buffer 
50mM Tris-HCl pH7.4 




1mM protease inhibitor cocktail 
 
Method 3 Cell Lysis Buffer 
50mM Tris pH7.4 










1mM protease inhibitors 
 
Method 3 IP Buffer 





X-Gal Staining Solution 
0.025g potassium ferricyanide 
0.032g potassium ferrocyanide 
30µl 1M MgCl 














7.1  CD31 Mutant Cytoplasmic Domain Construction 
7.1.1 The Discovery of CD31 
A 135kDa protein was identified from monoclonal antibody Hec7 screening of 
endothelial cell proteins, and found to localise at intracellular junctions on the surface 
of endothelial cells in vitro and  in vivo 49. 
CD31 was first identified from an endothelial expression library, where positive 
clones were revealed by epitope selection.  The positive clones reacted against a 
130kDa protein found at intracellular junctions, and was designated platelet-
endothelial cell adhesion molecule-1 (PECAM-1) 180.  In HUVEC (human umbilical 
cord endothelial cells) a monoclonal antibody panel was used to screen for protein 
localised to cell-cell contacts.  A cDNA library was produced from proliferating 
HUVEC, and positive clones, identifying CD31 were produced by transient 
transfection of Cos cells 181. 
 
7.1.2 CD31 Cloning 
CD31 (wild-type and tyrosine mutants) was cloned into pcDNA3 (Figure 7.1:1) from 
a cDNA library, and then PCR amplified into pGEX 4T (Figure 7.1:2) for protein 
production 63.  I have amplified wild-type, tyrosine mutant (Y663F, Y686F, 
Y663F/Y686F, Y701F) and serine mutant (S620A, S669A, S673A, S702A-designated 
QSA) CD31 cytoplasmic domains from pcDNA3 constructs (Dr Michael Douglas, 






SNNEK and lysine mutants from wild-type CD31 in pcDNA3.   For SNNEK and 
lysine mutants, and truncated constructs amplification was from full-length wild type 
CD31 in pcDNA3.  The PCR products were amplified to include 5’ Bam HI site and 
either a Sal I or Not I 3’ site.  The fragments were subcloned into pGEMTeasy (Figure 
7.1:3).  Taq polymerase adds overhanging A bases which enable the PCR fragments 
to be cloned in either way into pGEMTeasy due to its overhanging T bases. The PCR 
fragments were then cloned into pGEX 4T for protein production.   
DNA and amino acid sequence of CD31 cytoplasmic domain shows the position of 
the tyrosines (mutated to phenylalanine) and serines (mutated to alanine) (Figure 
7.1:4).  A diagrammatic representation of each of the constructs generated shows the 
N-terminal GST tag and position of mutations and truncations (Figure 7.1:5 and 















Figure 7.1:1.  pcDNA3 (Invitrogen) vector map showing the restriction sites available 
and the ampicillin resistance gene.  CD31 was cloned into this vector using BamH I and 


















Figure 7.1:2.  pGEX 4T (Amersham) vector map showing the ampicillin resistance gene, 
the N-terminal GST tag and the restriction sites available.  CD31 was cloned into this 









Figure 7.1:3.  pGEMTeasy (Promega) vector map showing the restriction sites 
available.  CD31 PCR products were subcloned directly into this vector by virtue of the 















Figure 7.1:4.  DNA sequence of the cytoplasmic domain of CD31 showing the tyrosine 










Figure 7.1:5.  GST-CD31 constructs showing position of tyrosine and serine mutations. 
Key to residues mutated
Serines 620, 669, 673, 702
















































Figure 7.1:7.  Site-directed mutagenesis constructs. 
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7.1.3 PCR and Subcloning 
The programme for PCR amplification, the primers used and the restriction sites 
added to all constructs are shown (Table 7.1:10). 
The CD31 cytoplasmic domain fragments (wild-type, tyrosine and serine mutants) of 
400bp (Figure 7.1:12 and Figure 7.1:13) were amplified from pcDNA3 vectors 
incorporating a 5’ Bam HI and 3’ Sal I restriction site.  Truncated and SNNEK and 
lysine mutants were also amplified from pcDNA3 (Figure 7.1:14 and Figure 7.1:15).  
The PCR fragments were gel extracted using Qiagen spin gel extraction kit and 
subcloned into pGEMTeasy.  The ligation reactions were transformed into DH5α 
competent cells and selected on LB agar supplemented with ampicillin 100mg/ml. 
Blue/white screening was utilised to select for positive clones.  Clones were grown up 
in LB supplemented with ampicillin 100μg/ml.  Plasmid DNA was extracted using 
Qiagen spin miniprep kit and sequenced.  Primer sequences used to verify for each 
construct are shown (Table 7.1:11).   
 
7.1.4 Cloning into pGEX 4T 
The pGEMTeasy plasmids were digested with Bam HI and Sal I or Not I restriction 
enzymes (Figure 7.1:16).  The resulting digest was run out on 1% agarose gel and the 
fragment extracted with Qiagen Spin gel extraction kit.  The fragments were then 
cloned into the pGEX 4T containing an N-terminal glutathione-S-transferase 
sequence, then transformed into XL-1 blue competent cells and selected on LB agar 
supplemented with ampicillin 100mg/ml.   Plasmids were purified using Qiagen 







7.1.5 Talin Reconstitution and Protein Purification 
The talin FERM domain construct in pET15b (Figure 7.1:8) was reconstituted from 
filter paper as described (see Materials and Methods) and transformed into XL-1 Blue 
for maxiprep extraction.  The plasmid was sequenced to confirm correct orientation 
using primers described in Table 7.1:11.  The purified plasmid was transformed into 

















Figure 7.1:8.  pET15b vector map with N-terminal his tag sequence, multiple cloning 






















































BamHI and Sal I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 











Bam HI and Sal I 94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 











BamHI and Not I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 












BamHI and Sal I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 
















BamHI and Sal I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 











BamHI and Sal I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 












BamHI and Not I 94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 
72°C for 5 minutes. 
 
Site Directed mutagenesis 
















BamHI and Sal I 94˚ C for 2 minutes and 30 
seconds 
twenty two cycles of 94˚C 
for 30 seconds 
53˚C for 40 seconds 
72˚C for 40 seconds 

























Site directed mutagenesis 
PCR with super primer to 
generate mutant  pcDNA3 
plasmid 
Primer as super primer Bam HI and Sal I 94˚C for 2 minutes and 30 
seconds 
sixteen cycles of 94˚C for 1 
minute 
53˚C for 45 seconds 
68˚C for 10 minutes 






CD31 K54A, CD31 
K85A/K86A cytoplasmic 
domain amplification from 





BamHI and Sal I  94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 










BamHI and Sal I  
 
94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 








72°C for 30 seconds then 













BamHI and Sal I  
 
94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 

















Bam HI Sal I 
 
94°C for 2 minutes 30 
seconds  
twenty-two cycles of 94°C 
for 30 seconds 
52°C for 30 seconds 
72°C for 30 seconds then 
72°C for 5 minutes. 
 
Table 7.1:10.  Primers, restriction sites and PCR programme included in PCR of CD31 







































7.1.6 Protein Induction 
Protein production was initiated by pGEX 4T1 plasmid transformation into BL21 
electrocompetent bacteria, and protein production was induced by the addition of 
IPTG (Figure 7.1:18, Figure 7.1:19 and Figure 7.1:20).  Protein was purified by GST 
















Figure 7.1:12.  Wild-type CD31 PCR product at 400bp incorporating 5’ Bam HI and 3’Sal 









Figure 7.1:13.  PCR of tyrosine and serine mutant CD31 cytoplasmic domains.  The 




































Figure 7.1:14.  Truncated CD31 PCR fragments CD31TM30,Δ88 (100bp), CD31TMΔ25,93 



































































Figure 7.1:16.  pGEMTeasy (3kb) digested with Bam HI and Sal I liberates the CD31 









Figure 7.1:17.  pGEX (5kb) digested with Bam HI and Sal I to check correct orientation 




















Figure 7.1:18.  Bacterial lysates from each clone, production of recombinant protein 
(40kDa) was only initiated by the addition of IPTG, separated on 10% acrylamide and 











Figure 7.1:19.  Truncated GST-CD31 recombinant proteins (CD31TM30Δ88 28kDa; 
CD31ΔTM25 37.5kDa; CD31ΔTM31 37kDa; CD31ΔTM50 34.5kDa; CD31ΔTM104 38.4kDa) 
showing IPTG induces protein production separated on 10% acrylamide and stained 













































































Figure 7.1:20.  SNNEK and lysine mutant recombinant proteins (40kDa) showing 










Figure 7.1:21.  Purified GST (25kDa), wild-type and mutant CD31 proteins (40kDa) 



































































Figure 7.1:22.  Truncated GST-CD31 constructs purified from bacteria.  10µl loaded 












Figure 7.1:23.  SNNEK and lysine mutant purified recombinant proteins (40kDa) 












































































7.2 Troubleshooting GST Pulldowns 
This section outlines the methodology used to optimise the method for the GST 
pulldown work in Chapter 3. 
The investigation originally started with GST pulldowns adapting the method from 60 
for use with Jurkats. Briefly the method is cell lysis and clearance of supernatant, then 
recombinant protein was added, then glutathione-agarose beads.  The beads were then 
washed in pulldown buffer (50mM Tris pH 7.4, 100mM NaCl, 0.5% Tween 20, 
10mM β-mercaptoethanol), and then the recombinant proteins plus any bound 
proteins were eluted with 5mM glutathione buffer.  When used with GST, wild-type, 
Y663F, Y686F, Y663F/Y686F, Y701F and QSA constructs and blotted for SHP-2 
(binds to phosphorylated CD31 cytoplasmic domain), there was non-specific binding 
to the GST alone (Figure 7.2:1).   
 
7.2.1 Increasing Salt Concentration 
To attempt to eliminate non-specific binding the salt concentration was increased in 
the pulldown buffer that was used to wash the beads from 100mM to 500 and 750mM 
and blotted for SHP-2  and Hsp90 (see chapter 3 for study on CD31 and Hsp90 
interactions).   There was also non-specific binding to the GST (Figure 7.2:2).  The 
lysate was precleared with either beads or GST before the pulldown, but this had no 
effect on non-specific binding (Figure 7.2:3).   
The process was re-examined again, and the protocol changed slightly to 
accommodate extra wash steps.  The cells were lysed as previously described and 






100mM β-mercaptoethanol, to reduce the glutathione on the beads then in 10mM Tris 
pH8 to removes excess mercaptoethanol.  The washed beads were then incubated with 
the protein/lysate as described.  The beads were then washed in 20mM Tris pH8 and 
200mM NaCl to remove weak i.e. non-specific interactions, then with 20mM Tris 
pH8 and 200mM NaI. NaI acts as a chaotropic agent to disrupt salt bridges and 
hydrophobic bonds.  This may help to remove non-specific binding to the GST which 
may have been promoted by increasing the salt concentration.  The pulldowns were 
then blotted for SHP-2 and Hsp90, however these conditions did not remove the non-
specific binding (Figure 7.2:4). 
The salt was removed from the system, and performed the GST pulldown again, 
collecting each wash fraction and blotting for SHP-2 and Hsp90.  There was still non- 










Figure 7.2:1.  GST pulldown from CD31 negative Jurkat lysates showing non-specific 











Figure 7.2:2.  GST pulldown with GST or GST-CD31 with different salt concentrations in 


















































Figure 7.2:3.  GST and CD31 pulldowns precleared with either GST alone or beads 













Figure 7.2:4.  GST pulldowns blotted for SHP-2 and Hsp90 with a NaCl wash and a NaI 







































































Figure 7.2:5.  GST pulldowns with 5 X106 CD31 negative Jurkats, washed with 5ml cell 
lysis buffer (no salt) and each wash fraction collected and blotted for Hsp90 showing 







Figure 7.2:6.  GST pulldowns with 5 X106 CD31 negative Jurkats, with the elution 





















































































Figure 7.2:7.  Three different methods of GST pulldown showing no binding of SHP-2 












Figure 7.2:8.  Three methods of GST pulldown blotted for tyrosine phosphorylated 











































Figure 7.2:9.  Recombinant proteins are tyrosine phosphorylated by recombinant src, 










Figure 7.2:10.  GST pulldowns with recombinant proteins phosphorylated with 
recombinant src by three different methods blotted for SHP-2 shows method 2 to 
provide the least amount of non-specific binding.   























































7.2.2 Literature Search 
The whole approach was reconsidered and a literature search performed for GST 
pulldowns with leukocytes.  Three methods were chosen, 182 used Jurkats, 183 used the 
same manufacturer of agarose beads and 184 are a group that works extensively on 
CD31.  All lysis was carried out on ice for 20 minutes (checked by trypan blue 
exclusion), with lysis buffer at a concentration of 1ml per 10 million cells, before 







Table 7.2:1.  Buffer ingredients and methodology for GST pulldown trialled. 
Method Lysis buffer Pulldown Method and Wash Reference 






1mM protease inhibitor 
cocktail 
Beads combined with recombinant protein 
Add beads to lysate for 90 minutes 
Wash beads three times in lysis buffer 
Beads Resuspended in sample buffer 
182 
2 50mM Tris-HCl pH7.4 




1mM protease inhibitor 
cocktail 
Cell lysate precleared with agarose beads 
overnight 
Beads combined with recombinant protein 
Beads added to precleared lysate for 2 hours 
Beads washed three times in lysis buffer and 
once with PBS 
Beads resuspended in PBS and sample buffer 
183 
3 Lysis buffer: 
50mM Tris pH7.4 





1mM protease inhibitors 
IP buffer: 




Beads combined with recombinant protein 
Beads added to lysate for 2 hours 
IP buffer added for 2 hours 
Beads washed with IP buffer 








7.2.3 Requirement for Phosphorylation 
The three methods were blotted for SHP-2 and Hsp90 (Figure 7.2:7), but no SHP-2 
was detected as binding to CD31.    As it has been previously shown that SHP-2 binds 
to tyrosine phosphorylated cytoplasmic domain of CD31, phosphotyrosine was 
probed for.  As expected there was no phosphorylation of recombinant proteins by 
virtue of them being in the cell lysate, or by being produced by the bacteria (Figure 
7.2:8). 
The recombinant proteins were phosphorylated with recombinant src kinase 56 (Figure 
7.2:9) and used the phosphorylated protein in GST pulldowns with the three methods 
again.  When blotting for SHP-2 (Figure 7.2:10), method 1 showed non-specific 
binding to the GST alone, and a strong band with wild-type CD31.  Method 2 shows 
less non-specific binding with GST alone, and a good band with wild type CD31.  
Method 3 shows non-specific binding to the GST, and good binding to wild-type 
CD31.  It was decided that method 2 provided the least amount of background 
binding, and was used in all subsequent GST pulldowns. 
 
7.3 Troubleshooting Jurkat Transfection 
7.3.1 Amaxa Transfection  
To provide a positive control for transfection, the Amaxa electroporation protocol 
includes a GFP vector.  Transfecting CD31 positive Jurkats with this vector should 
indicate the transfection efficiency, and several programmes are recommended for the 
Jurkat cell line, including a programme specifically for use with Jurkats that have 






GFP vector was transfected into the Jurkats as per the manufacturer’s instructions, and 
the cells harvested after 24hrs incubation, and analysed by flow cytometry (Figure 
7.3:1and Figure 7.3:2).  The number of GFP positive cells was very low, showing the 
transfection efficiency to be well below that which would allow testing the effects of 



































Figure 7.3:1.  CD31 positive Jurkats transfected with GFPmax vector (Amaxa) or mock 
control using Amaxa protocol and transfection programmes A-17, C-16 and G-10 show 
low transfection efficiency.  Marker indicates percentage GFP positive cells compared 
with mock transfected cells.  
Ungated

































































































Figure 7.3:2.  CD31 positive Jurkats transfected with GFPMax vector (Amaxa) using 
Amaxa protocol and transfection programmes I-10 (for previously transfected cells), and 
S-18 shows low transfection efficiency. 
Ungated




































As MM6 cells also express both SHP-1 and SHP-2, attempts were made to transfect 
these cells initially with the GFP vector as a positive control.  However, we were unable 
to demonstrate convincing transfection of MM6 with GFP (Figure 7.3:3); therefore the 


























Figure 7.3:3.  MM6 cells transfected with GFPMax vector and Amaxa programmes 
provided by Amaxa customer data show low transfection efficiency. 
 




































































7.3.2 SHP-2 siRNA Constructs 
A human SHP-2 sequence 185 was used to generate an siRNA construct.  As a positive 
control of transduction and silencing, human lamin A/C 186 was also cloned, and a 
scrambled sequence 187 was used as a negative control (Figure 7.3:4).  These constructs 
were to be cloned into a modified pLenti 6 plasmid vector for transcription.  The 
modified vector contains the human H1 promoter, for transcription of short hairpin RNA 
in mammalian cells 188 and CMV-GFP promoter, so when packaged, the transduced cells 
produce GFP and can be sorted if desired.  However, although time constraints did not 
permit this to occur, we would predict that knock-down of SHP-2 in CD31 positive 
Jurkats might impair their detachment from THP-1.   
 
To produce the lentiviral vector for packaging the SHP-2 siRNA constructs, a modified 
pLenti vector would have been created that would express the constructs in mammalian 
cells under the H1 promoter.  The original pLenti vector (Figure 7.3:5) was to be 
modified to remove the topoisomerase site and existing promoters via restriction digest 
with Cla I and Bcl I.  A short oligo was then ligated into this region which contained a 
multiple cloning site with Cla I, Bam HI and Bcl I sites.  The mammalian promoter H1 
and the CMV-GFP promoter was amplified by PCR from a mammalian expression 
plasmid and inserted into the blunt TOPO vector (Figure 7.3:6) to give an intermediate 
vector into which the siRNA constructs could firstly be annealed to create double-






construct, the H1 and CMV-GFP promoter could be cut out via Bgl II digestion and 
ligated into the modified pLenti vector via the Bam HI site.  This ligation is possible due 
to Bgl II cutting at sequence A GATCT and Bam HI cutting at G GATCC, which leaves 
the same sticky end to anneal the fragments to (Figure 7.3:7 shows whole scheme).  The 
plasmid could then be transfected into the packaging cell line and virus produced with 
















Figure 7.3:4.  SHP-2, lamin A/C and scrambled siRNA hairpin constructs to be generated 
with Sal I and Hind III restriction sites and a loop for cloning into pLenti MCS-H1.CMV-









Figure 7.3:5.  pLenti vector (Invitrogen) from which the topoisomerase sites and promoter 
region was to be removed by restriction digest and replaced with a short oligo containing 
a multiple cloning site with restriction sites Cla I, Bam HI and Bcl I.  
Region removed




5’-AGCTG GGC AGTTCTC AAAAA TTCGAA-3’COMPL.SHP-2 COMPL.SHP-2 
STOP Hind III
5’-TCGAC CCG TCAAGAG TTTTT
Sal I
Lamin A/C Lamin A/C 
Loop
5’-AGCTG GGC AGTTCTC AAAAACOMPL.Lamin A/C COMPL.Lamin A/C 
STOP Hind III






















Figure 7.3:6.  Blunt vector containing the mammalian H1 and CMV-GFP promoters which 
was to have the siRNA constructs ligated in and then cut from this vector and ligated into 



















Figure 7.3:7.  Schematic showing cloning strategy of siRNA constructs by annealing 
fragments, ligating into an intermediate blunt vector and then restriction digest to remove 
the siRNA sequence and H1 and CMV-GFP promoter, then finally ligating into the 
modified pLenti as described previously (Scheme courtesy of Dr Jason King, University 
of Edinburgh, UK).








































Insert into SalI-Hind III
Anneal primers. Insert
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